pamidronate has been researched along with Milk-Alkali Syndrome in 311 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the efficacy and safety of pamidronate in HD patients affected by severe secondary hyperparathyroidism and moderate hypercalcemia who were receiving intravenous calcitriol (Calcijex)." | 9.10 | Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. ( Fuster, D; Mas, M; Moreno, A; Torregrosa, JV; Ybarra, J, 2003) |
| "To compare the efficacy and safety of ibandronate and pamidronate in patients with hypercalcemia of malignancy (HCM)." | 9.10 | Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. ( Bergström, B; Pecherstorfer, M; Rizzoli, R; Steinhauer, EU; Wetterwald, M, 2003) |
| "To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy." | 9.09 | Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. ( Costello, S; Glück, S; Heffernan, M; Hortobagyi, GN; Kennedy, I; Knight, RD; Leff, R; Lipton, A; Mellars, K; Reitsma, DJ; Seaman, JJ; Simeone, J; Stewart, JF; Theriault, RL, 1999) |
| "Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy." | 9.08 | Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. ( Ballester, O; Bell, R; Berenson, JR; Blacklock, HA; Bordoni, R; Dimopoulos, MA; George, S; Heffernan, M; Keller, A; Knight, RD; Kovacs, MJ; Lichtenstein, A; Lipton, A; Porter, L; Reitsma, DJ; Seaman, J; Simeone, J, 1996) |
| "A group of 38 female patients with advanced breast cancer experiencing the first occurrence of tumour-induced hypercalcaemia (TIH), mostly with osteolytic progressive bone metastases, were included in a prospective calcaemia-adapted study using three different doses of pamidronate (30 mg, 45 mg and 60 mg)." | 9.08 | Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia. ( Mitrović, L; Nesković-Konstantinović, Z; Petrović, J; Ristović, Z; Stamatović, L, 1995) |
| "Women with stage IV breast cancer who were receiving cytotoxic chemotherapy and had at least one lytic bone lesion were given either placebo or pamidronate (90 mg) as a two-hour intravenous infusion monthly for 12 cycles." | 9.08 | Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Hortobagyi, GN; Knight, RD; Lipton, A; Porter, L; Seaman, J; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1996) |
| "The superiority of pamidronate in controlling hypercalcemia is mirrored by the changes observed in these markers." | 9.08 | Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. ( Coleman, RE; Eastell, R; Guo, CY; Purohit, OP; Vinholes, J, 1997) |
| "We assessed the effects of 60-mg single doses of pamidronate disodium compared with saline alone in the treatment of cancer-associated hypercalcemia." | 9.07 | Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. ( Ahmann, F; Chapman, R; Gill, I; Gucalp, R; Heffernan, M; Knight, RD; Madajewicz, S; Navari, R; Theriault, R; Zelenakas, K, 1994) |
| "To determine the efficacy, dose-response relationship, and safety of 30, 60, and 90 mg of a single intravenous dose of an aminobisphosphonate, pamidronate (APD), for the treatment of moderate to severe hypercalcemia of malignancy." | 9.07 | Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. ( Chapman, R; Gagel, RF; Henderson, IC; Mallette, LE; Nussbaum, SR; Vandepol, CJ; Younger, J; Zubler, MA, 1993) |
| "We have conducted a randomized crossover comparative trial of a single-dose course of disodium (3-amino-1-hydroxypropylidene) bisphosphonate pentahydrate (pamidronate) and plicamycin in 48 patients with a first occurrence of tumor-related hypercalcemia." | 9.07 | Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial. ( Senn, HJ; Thiébaud, D; Thürlimann, B; Waldburger, R, 1992) |
| "This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate disodium (EHDP) in the treatment of cancer-related hypercalcemia." | 9.07 | Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. ( Gucalp, R; Keller, A; Mallette, LE; Neidhart, J; Richman, SP; Ritch, P; Sarma, PR; Siegel, R; Tauer, K; Wiernik, PH, 1992) |
| "The improved efficacy of zoledronic acid compared with pamidronate disodium has been demonstrated in a pooled analysis of two randomized clinical trials in patients with hypercalcemia of malignancy." | 8.81 | The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. ( Major, P, 2002) |
| "Two identical, concurrent, parallel, multicenter, randomized, double-blind, double-dummy trials were conducted to compare the efficacy and safety of zoledronic acid and pamidronate for treating hypercalcemia of malignancy (HCM)." | 8.81 | Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. ( Abdi, E; Bell, R; Body, J; Hon, J; Lortholary, A; Major, P; Menssen, HD; Mills, G; Quebe-Fehling, E; Seaman, J; Yunus, F, 2001) |
| "Salmon calcitonin has been used for the management of acute hypercalcemia for the past several years." | 8.78 | Salmon calcitonin in the acute management of hypercalcemia. ( Wisneski, LA, 1990) |
| "The primary objective was to compare the incidence of acute kidney injury (AKI) within 7 days of receiving pamidronate for the treatment of HCM with pre-existing renal dysfunction versus normal renal function at the time of pamidronate administration." | 8.02 | Use of Pamidronate for Hypercalcemia of Malignancy in Renal Dysfunction. ( Norman, SJ; Reeves, DJ; Saum, LM, 2021) |
| "This is a case report of a patient who developed severe, irreversible hypocalcemia after receiving one dose of pamidronate 90 mg for hypercalcemia of malignancy." | 7.91 | A case of severe, irreversible hypocalcemia after one dose of pamidronate administered for hypercalcemia of malignancy. ( Kim, S, 2019) |
| " Acute renal failure due to severe hypercalcemia and nephrocalcinosis treated with two doses of pamidronate in an infant with Williams-Beuren syndrome." | 7.88 | Acute renal failure due to severe hypercalcemia and nephrocalcinosis treated with two doses of pamidronate in an infant with Williams-Beuren syndrome. ( Baş, VN; Baştuğ, F; Çetinkaya, H; Nalçacıoğlu, H; Tekatlı-Çelik, B; Yel, S, 2018) |
| " We report a case in which a patient with tertiary hyperparathyroidism and refractory hypercalcemia who was not a surgical candidate was managed with the bisphosphonate pamidronate." | 7.75 | Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient. ( Canada, RB; Czosnowski, LM; Hudson, JQ, 2009) |
| " When conventional treatment of hypercalcemia failed, pamidronate dramatically decreased both the calcium levels and the frequency of uterine contractions." | 7.73 | Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions. ( Culbert, EC; Schfirin, BS, 2006) |
| "To describe extreme hypercalcemia as the presenting feature of acute lymphoblastic leukemia in an 8-yr-old girl and the combined use of pamidronate and calcitonin for its treatment." | 7.72 | Treatment of acute lymphoblastic leukemia-induced extreme hypercalcemia with pamidronate and calcitonin. ( Goldman, GM; Mathur, M; Rao, SP; Saxena, VR; Sykes, JA, 2003) |
| "The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism." | 7.72 | Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Lin, SH; Lin, YF; Lu, KC; Yeung, LK, 2003) |
| "We commend the short-term use of pamidronate in neonatal severe hyperparathyroidism to treat extreme hypercalcaemia and halt hyperparathyroid-driven skeletal demineralisation in preparation for parathyroidectomy." | 7.72 | Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy. ( Cheetham, T; Cranston, T; Kurzawinski, T; Pearce, S; Spitz, L; Thakker, R; van't Hoff, WG; Waller, S, 2004) |
| "To report the efficacy of Pamidronate to treat hypercalcaemia in a patient with Williams-Beuren syndrome (WBS)." | 7.72 | Long-term control of hypercalcaemia in an infant with williams-Beuren syndrome after a single infusion of biphosphonate (Pamidronate). ( Gravano, JC; Mastaglia, SR; Mautalen, C; Oliveri, B; Pardo Argerich, L, 2004) |
| "To determine whether pamidronate is a safe and effective agent for the treatment of severe hypercalcemia of malignancy in children." | 7.70 | Use of pamidronate in the management of acute cancer-related hypercalcemia in children. ( Shende, A; Young, G, 1998) |
| "Pamidronate disodium, a bone resorption inhibitor through osteoclast mediation, has been used to treat chronic hypercalcemia secondary to malignancy and chronic renal failure." | 7.70 | The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication. ( Lee, DC; Lee, GY, 1998) |
| " He was treated with seven courses of combined chemotherapy (CDDP + etoposide), until he showed extreme hypercalcemia and acute renal failure." | 7.70 | [A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate]. ( Kametani, T; Koshida, H; Masuda, S, 1999) |
| "To review the use of pamidronate to treat immobilization hypercalcemia after acute spinal cord injury (SCI) in 9 cases." | 7.70 | Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury. ( Cardenas, DD; Massagli, TL, 1999) |
| "Two patients with malignancy-associated hypercalcemia from bone metastases of breast cancer, accompanied by consciousness disturbance, were treated by a combination therapy of pamidronate and salmon calcitonin." | 7.70 | [Two cases of malignancy-associated hypercalcemia from bone metastases of breast cancer successfully treated with combination therapy using pamidronate and calcitonin]. ( Aoki, T; Kaise, H; Koyanagi, Y; Kusama, M; Matsunaga, T; Nakamura, Y; Nakayama, S; Ota, D, 2000) |
| "The purpose of this study was to investigate the effects of pamidronate, a second generation bisphosphonate, on the change in calcium homeostasis in patients with tumor-associated hypercalcemia." | 7.69 | Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics. ( Ariyoshi, Y; Hasegawa, H; Niinomi, M; Oiso, Y; Sakiyama, N; Takano, T; Tomita, A; Yamamoto, M, 1994) |
| "Intravenous pamidronate disodium has been used successfully in the treatment of malignancy-associated hypercalcemia and Paget's disease of bone." | 7.69 | Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism. ( Graves, L; Tal, A, 1996) |
| "Pamidronate (APD) is a drug widely used for the treatment of hypercalcemia of malignancy." | 7.69 | Safety of pamidronate in patients with renal failure and hypercalcemia. ( Flombaum, CD; Machado, CE, 1996) |
| "A 65-year-old woman admitted for palliative care of metastatic renal/bladder carcinoma developed symptomatic hypocalcemia nine days following a single dose of pamidronate." | 7.69 | Symptomatic hypocalcemia after intravenous pamidronate. ( Bruera, E; McIntyre, E, 1996) |
| "Pamidronate is a second generation bisphosphonate used for treating tumor-induced hypercalcemia and for preventing the development of new bone metastasis." | 7.69 | [Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma]. ( Arima, K; Hioki, T; Kawamura, J; Kise, H; Kobayashi, K; Sugiura, Y; Tochigi, H; Yanagawa, M, 1996) |
| "The response to the bisphosphonate, pamidronate, is reported in a child with osteogenesis imperfecta who had recurrent symptomatic hypercalcaemia after immobilisation following fractures." | 7.69 | Hypercalcaemia in osteogenesis imperfecta treated with pamidronate. ( Ball, RJ; Smith, RA; Wilkinson, H; Williams, CJ, 1997) |
| "Hypercalcemia in a 4-year-old boy with non-Hodgkin lymphoma treated with pamidronate is presented." | 7.69 | Childhood cancer and hypercalcemia: report of a case treated with pamidronate. ( Akyüz, C; Büyükpamukçu, M; Hazar, V; Kutluk, MT; Varan, A, 1997) |
| " The time course study on the antihypercalcemic effect of pamidronate was performed using a rat hypercalcemia model induced by orally administered cholecalciferol." | 7.68 | Effect of pamidronate in a rat hypercalcemia model induced by cholecalciferol. ( Hasegawa, Y; Inukai, T; Noguchi, S; Okada, M, 1992) |
| "Pamidronate (aminopropylidene diphosphonate, APD) is known to be an effective agent in lowering plasma calcium in cancer associated hypercalcaemia and in primary hyperparathyroidism." | 7.68 | [Combination therapy with pamidronate and calcitonin in hypercalcemic crisis caused by primary hyperparathyroidism]. ( Christensen, JH; Kristiansen, JH, 1992) |
| "The effect of lowering ionized calcium on circulating parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP) was assessed in twenty patients with hypercalcemia of malignancy following treatment with Pamidronate Disodium." | 7.68 | Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD). ( Grill, V; Ho, PW; Jerums, G; Martin, TJ; Murray, RM; Pitt, P; Potts, C; Santamaria, JD, 1992) |
| "Nine patients (median age, 81 years) with primary hyperparathyroidism were treated with intravenous infusions of disodium pamidronate (APD), which is a bisphosphonate drug." | 7.68 | Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. ( Jansson, S; Lindstedt, G; Lundberg, PA; Tisell, LE, 1991) |
| "Seventeen patients with malignant hypercalcemia were treated with a combination of a single dose of 3-amino 1-hydroxypropylidene-1-bisphosphonate (APD [also known as AHPrBP or palmidronate disodium]) and salmon calcitonin given as suppositories for 3 days." | 7.68 | Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. ( Burckhardt, P; Jacquet, AF; Thiébaud, D, 1990) |
| "Pamidronate treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia." | 6.69 | Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. ( Abildgaard, N; Brincker, H; Ford, J; Gimsing, P; Hedenus, M; Kandra, A; Turesson, I; Westin, J, 1998) |
| "Pamidronate was given in a single infusion on day 0, the dose of pamidronate adapted to the severity of hypercalcemia." | 6.67 | [Pamidronate in the treatment of tumor-associated hypercalcemia]. ( Bosse, C; Fortelny, A; Gerber, E; Janisch, S; Lenzhofer, R; Marosi, C; Pecherstorfer, M; Rainer, H; Schratzberger, W; Wogritsch, C, 1991) |
| " Review of the published literature suggests that a clinically relevant dose-response relationship exists in the dose range 30-60 mg; most hypercalcemic patients will achieve normocalcemia with a dose of 60 mg pamidronate or more." | 6.39 | Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects? ( Thürlimann, B, 1994) |
| "This study demonstrates that Pam is effective and safe for treating PTHRH, while ensuring close laboratory monitoring of calcium and phosphorus metabolism." | 5.62 | Efficacy and Safety of Intravenous Pamidronate for Parathyroid Hormone-dependent Hypercalcemia in Hospitalized Patients. ( Barzilay-Yoseph, L; Klein, N; Ramaty, E; Rosenblum, RC; Rotman-Pikielny, P; Twito, O, 2021) |
| "BACKGROUND Hypercalcemia is a common complication in the intensive care unit (ICU)." | 5.48 | Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report. ( El Madhoun, I; El Zeer, HS; Khatib, M; Mahmoud, S; Mitwally, H, 2018) |
| "Pamidronate has a beneficial effect in those patients with IIH where glucocorticoids and furosemide fail to meet the expectations." | 5.39 | Intravenous pamidronate in the treatment of severe idiopathic infantile hypercalcemia. ( Bayer, M; Cerna, L; Konrad, M; Kutilek, S; Schlingmann, KP; Skalova, S, 2013) |
| "Subcutaneous fat necrosis of the newborn (SCFN) is a panniculitis that develops in fatty areas during the first weeks of life after foetal distress or perinatal complications." | 5.35 | Effectiveness of pamidronate in severe neonatal hypercalcemia caused by subcutaneous fat necrosis: a case report. ( Bollani, L; Cabano, R; Del Forno, C; Lombardi, G; Stronati, M, 2009) |
| "Treatments of hypercalcemia have included hydration, furosemide and corticosteroids." | 5.33 | Pamidronate: Treatment for severe hypercalcemia in neonatal subcutaneous fat necrosis. ( Alos, N; Chabot, G; Eugène, D; Fillion, M; Kokta, V; Powell, J, 2006) |
| "The use of pamidronate for treatment of hypercalcemia and chronic conditions that affect normal bone growth is increasing in children." | 5.32 | Pamidronate treatment for hypercalcemia in an infant receiving parenteral nutrition. ( Bryowsky, JJ; Bugnitz, MC; Hak, EB, 2004) |
| "Although treatment of hypercalcemia with pamidronate is palliative, it is effective against the deterioration of quality of life." | 5.31 | [Treatment of hypercalcemia of malignancy with pamidronate in a patient with advanced recurrent oral cancer]. ( Hashitani, S; Matsushita, Y; Nishimura, N; Noguchi, K; Takaoka, K; Urade, M, 2002) |
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 5.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| "Parathyroid carcinoma is rare and the associated hypercalcaemia is often resistant to all treatment." | 5.29 | Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate. ( Braatvedt, GD; Corrall, RJ; Newrick, PG; Sheffield, E; Webb, AJ, 1994) |
| "The aim of this study was to evaluate the efficacy and safety of pamidronate in HD patients affected by severe secondary hyperparathyroidism and moderate hypercalcemia who were receiving intravenous calcitriol (Calcijex)." | 5.10 | Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. ( Fuster, D; Mas, M; Moreno, A; Torregrosa, JV; Ybarra, J, 2003) |
| "To compare the efficacy and safety of ibandronate and pamidronate in patients with hypercalcemia of malignancy (HCM)." | 5.10 | Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. ( Bergström, B; Pecherstorfer, M; Rizzoli, R; Steinhauer, EU; Wetterwald, M, 2003) |
| " infusion of pamidronate 90 mg in the treatment of malignant hypercalcemia." | 5.10 | Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia. ( Atula, ST; Nevalainen, JI; Pylkkänen, LH; Tähtelä, RK, 2003) |
| "To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy." | 5.09 | Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. ( Costello, S; Glück, S; Heffernan, M; Hortobagyi, GN; Kennedy, I; Knight, RD; Leff, R; Lipton, A; Mellars, K; Reitsma, DJ; Seaman, JJ; Simeone, J; Stewart, JF; Theriault, RL, 1999) |
| "Bisphosphonates are now the standard treatment for tumor-induced hypercalcemia (TIH), and pamidronate can normalize serum Ca in at least 90% of the patients treated for the first time." | 5.09 | Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. ( Body, JJ; Dumon, JC; Louviaux, I, 2000) |
| "Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy." | 5.08 | Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. ( Ballester, O; Bell, R; Berenson, JR; Blacklock, HA; Bordoni, R; Dimopoulos, MA; George, S; Heffernan, M; Keller, A; Knight, RD; Kovacs, MJ; Lichtenstein, A; Lipton, A; Porter, L; Reitsma, DJ; Seaman, J; Simeone, J, 1996) |
| "A group of 38 female patients with advanced breast cancer experiencing the first occurrence of tumour-induced hypercalcaemia (TIH), mostly with osteolytic progressive bone metastases, were included in a prospective calcaemia-adapted study using three different doses of pamidronate (30 mg, 45 mg and 60 mg)." | 5.08 | Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia. ( Mitrović, L; Nesković-Konstantinović, Z; Petrović, J; Ristović, Z; Stamatović, L, 1995) |
| "Women with stage IV breast cancer who were receiving cytotoxic chemotherapy and had at least one lytic bone lesion were given either placebo or pamidronate (90 mg) as a two-hour intravenous infusion monthly for 12 cycles." | 5.08 | Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Hortobagyi, GN; Knight, RD; Lipton, A; Porter, L; Seaman, J; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1996) |
| "The superiority of pamidronate in controlling hypercalcemia is mirrored by the changes observed in these markers." | 5.08 | Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. ( Coleman, RE; Eastell, R; Guo, CY; Purohit, OP; Vinholes, J, 1997) |
| "We assessed the effects of 60-mg single doses of pamidronate disodium compared with saline alone in the treatment of cancer-associated hypercalcemia." | 5.07 | Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. ( Ahmann, F; Chapman, R; Gill, I; Gucalp, R; Heffernan, M; Knight, RD; Madajewicz, S; Navari, R; Theriault, R; Zelenakas, K, 1994) |
| "To determine the efficacy, dose-response relationship, and safety of 30, 60, and 90 mg of a single intravenous dose of an aminobisphosphonate, pamidronate (APD), for the treatment of moderate to severe hypercalcemia of malignancy." | 5.07 | Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. ( Chapman, R; Gagel, RF; Henderson, IC; Mallette, LE; Nussbaum, SR; Vandepol, CJ; Younger, J; Zubler, MA, 1993) |
| "We have conducted a randomized crossover comparative trial of a single-dose course of disodium (3-amino-1-hydroxypropylidene) bisphosphonate pentahydrate (pamidronate) and plicamycin in 48 patients with a first occurrence of tumor-related hypercalcemia." | 5.07 | Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial. ( Senn, HJ; Thiébaud, D; Thürlimann, B; Waldburger, R, 1992) |
| "This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate disodium (EHDP) in the treatment of cancer-related hypercalcemia." | 5.07 | Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. ( Gucalp, R; Keller, A; Mallette, LE; Neidhart, J; Richman, SP; Ritch, P; Sarma, PR; Siegel, R; Tauer, K; Wiernik, PH, 1992) |
| "The improved efficacy of zoledronic acid compared with pamidronate disodium has been demonstrated in a pooled analysis of two randomized clinical trials in patients with hypercalcemia of malignancy." | 4.81 | The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. ( Major, P, 2002) |
| "Two identical, concurrent, parallel, multicenter, randomized, double-blind, double-dummy trials were conducted to compare the efficacy and safety of zoledronic acid and pamidronate for treating hypercalcemia of malignancy (HCM)." | 4.81 | Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. ( Abdi, E; Bell, R; Body, J; Hon, J; Lortholary, A; Major, P; Menssen, HD; Mills, G; Quebe-Fehling, E; Seaman, J; Yunus, F, 2001) |
| " They now constitute the standard treatment for cancer hypercalcemia, for which we recommend a dose of 1,500 mg of clodronate or 90 mg of pamidronate; the latter compound is more potent and has a longer lasting effect." | 4.80 | Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. ( Bartl, R; Body, JJ; Burckhardt, P; Delmas, PD; Diel, IJ; Fleisch, H; Kanis, JA; Kyle, RA; Mundy, GR; Paterson, AH; Rubens, RD, 1998) |
| " In multiple myeloma, one study with oral clodronate has reported a decrease in bone events and two other studies, one with intravenous pamidronate and the other with oral clodronate have both reported a decrease in skeletal events and bone pain." | 4.80 | [Bisphosphonates and bone metastases]. ( Berthaud, P; Jadaud, E; Lortholary, A, 1999) |
| " Followed by hydration with saline, pamidronate is effective for the control of symptomatic hypercalcemia." | 4.79 | [Paraneoplastic syndrome]. ( Hara, N; Nakanishi, Y; Takayama, K, 1997) |
| "Recent information on the pathophysiology and treatment of hypercalcemia of malignancy is reviewed, and the roles of two new agents, gallium nitrate and pamidronate, are discussed." | 4.78 | Update on the medical treatment of hypercalcemia of malignancy. ( Hall, TG; Schaiff, RA, 1993) |
| "Salmon calcitonin has been used for the management of acute hypercalcemia for the past several years." | 4.78 | Salmon calcitonin in the acute management of hypercalcemia. ( Wisneski, LA, 1990) |
| "The primary objective was to compare the incidence of acute kidney injury (AKI) within 7 days of receiving pamidronate for the treatment of HCM with pre-existing renal dysfunction versus normal renal function at the time of pamidronate administration." | 4.02 | Use of Pamidronate for Hypercalcemia of Malignancy in Renal Dysfunction. ( Norman, SJ; Reeves, DJ; Saum, LM, 2021) |
| "No large study has been conducted to date to compare the effectiveness of prednisolone, alendronate and pamidronate as first-line treatment in children with hypercalcemia due to vitamin D intoxication." | 3.91 | Comparison of Treatment Regimens in Management of Severe Hypercalcemia Due to Vitamin D Intoxication in Children ( Anık, A; Atay, Z; Aycan, Z; Aydın, M; Bereket, A; Can Yılmaz, G; Çayır, A; Çetinkaya, S; Demir, K; Döneray, H; Eren, E; Kara, C; Kendirci, M; Orbak, Z; Özkan, B; Törel Ergür, A; Uçaktürk, A, 2019) |
| "This is a case report of a patient who developed severe, irreversible hypocalcemia after receiving one dose of pamidronate 90 mg for hypercalcemia of malignancy." | 3.91 | A case of severe, irreversible hypocalcemia after one dose of pamidronate administered for hypercalcemia of malignancy. ( Kim, S, 2019) |
| " Acute renal failure due to severe hypercalcemia and nephrocalcinosis treated with two doses of pamidronate in an infant with Williams-Beuren syndrome." | 3.88 | Acute renal failure due to severe hypercalcemia and nephrocalcinosis treated with two doses of pamidronate in an infant with Williams-Beuren syndrome. ( Baş, VN; Baştuğ, F; Çetinkaya, H; Nalçacıoğlu, H; Tekatlı-Çelik, B; Yel, S, 2018) |
| "Our results show that the majority of patients with breast cancer, who develop bony metastases in Newfoundland and Labrador, are initially treated with the bisphosphonate, pamidronate." | 3.79 | Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre. ( Edwards, S; Laing, K; McCarthy, J; McCrate, F; Murphy, L; Powell, E; Seal, M, 2013) |
| "Pamidronate has a pharmacologic profile similar to that of etidronate, but pamidronate is more potent and has a longer duration of effect." | 3.77 | Pamidronate. ( Kellihan, MJ; Mangino, PD, 1992) |
| " We report a case in which a patient with tertiary hyperparathyroidism and refractory hypercalcemia who was not a surgical candidate was managed with the bisphosphonate pamidronate." | 3.75 | Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient. ( Canada, RB; Czosnowski, LM; Hudson, JQ, 2009) |
| " Hypercalcemia and high serum level of calcitriol were found." | 3.74 | [Hypercalcaemia and malignant lymphoma. One case report]. ( Berrut, G; Foussard, C; Frein, D; Josselin, N; Lavigne, C; Moles, MP; Sivova, N, 2007) |
| " When conventional treatment of hypercalcemia failed, pamidronate dramatically decreased both the calcium levels and the frequency of uterine contractions." | 3.73 | Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions. ( Culbert, EC; Schfirin, BS, 2006) |
| "To describe extreme hypercalcemia as the presenting feature of acute lymphoblastic leukemia in an 8-yr-old girl and the combined use of pamidronate and calcitonin for its treatment." | 3.72 | Treatment of acute lymphoblastic leukemia-induced extreme hypercalcemia with pamidronate and calcitonin. ( Goldman, GM; Mathur, M; Rao, SP; Saxena, VR; Sykes, JA, 2003) |
| "The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism." | 3.72 | Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Lin, SH; Lin, YF; Lu, KC; Yeung, LK, 2003) |
| "We commend the short-term use of pamidronate in neonatal severe hyperparathyroidism to treat extreme hypercalcaemia and halt hyperparathyroid-driven skeletal demineralisation in preparation for parathyroidectomy." | 3.72 | Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy. ( Cheetham, T; Cranston, T; Kurzawinski, T; Pearce, S; Spitz, L; Thakker, R; van't Hoff, WG; Waller, S, 2004) |
| "To report the efficacy of Pamidronate to treat hypercalcaemia in a patient with Williams-Beuren syndrome (WBS)." | 3.72 | Long-term control of hypercalcaemia in an infant with williams-Beuren syndrome after a single infusion of biphosphonate (Pamidronate). ( Gravano, JC; Mastaglia, SR; Mautalen, C; Oliveri, B; Pardo Argerich, L, 2004) |
| "Treatment of immobilization hypercalcemia in these two patients with pamidronate was successful." | 3.71 | Immobilization hypercalcemia in critical illness following bariatric surgery. ( Alborzi, F; Leibowitz, AB, 2002) |
| "The most serious, potentially life-threatening manifestation of 'flare' is hypercalcemia, registered in 4-5% of breast cancer patients with bone metastases, usually during the first few weeks of tamoxifen treatment." | 3.71 | Tumor 'flare' hypercalcemia--an additional indication for bisphosphonates? ( Jelic, S; Mitrović, L; Nikolic-Tomasević, Z; Popov, I; Radosavljević, D, 2001) |
| "To determine whether pamidronate is a safe and effective agent for the treatment of severe hypercalcemia of malignancy in children." | 3.70 | Use of pamidronate in the management of acute cancer-related hypercalcemia in children. ( Shende, A; Young, G, 1998) |
| "Clodronate, etidronate and pamidronate are bisphosphonates introduced in the treatment of hypercalcaemia and osteoporosis." | 3.70 | Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. ( Kalliovalkama, J; Kankaanranta, H; Lähteenmäki, T; Pörsti, I; Salenius, JP; Sisto, T; Wu, X; Ylitalo, P; Ylitalo, R, 1998) |
| "Pamidronate disodium, a bone resorption inhibitor through osteoclast mediation, has been used to treat chronic hypercalcemia secondary to malignancy and chronic renal failure." | 3.70 | The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication. ( Lee, DC; Lee, GY, 1998) |
| "The successful use of pamidronate, a bisphosphonate, for the treatment of hypercalcemia and/or osteopenia is reported in three children with renal failure or following renal transplant." | 3.70 | The use of pamidronate in three children with renal disease. ( Rodd, C; Sellers, E; Sharma, A, 1998) |
| " He was treated with seven courses of combined chemotherapy (CDDP + etoposide), until he showed extreme hypercalcemia and acute renal failure." | 3.70 | [A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate]. ( Kametani, T; Koshida, H; Masuda, S, 1999) |
| "To review the use of pamidronate to treat immobilization hypercalcemia after acute spinal cord injury (SCI) in 9 cases." | 3.70 | Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury. ( Cardenas, DD; Massagli, TL, 1999) |
| "To determine whether pamidronate disodium can reduce vitamin D3-induced hypercalcemia in dogs and whether combination treatment with calcitonin is more effective than treatment with pamidronate alone." | 3.70 | Use of pamidronate to reverse vitamin D3-induced toxicosis in dogs. ( Braselton, WE; Chiapuzio, CL; Fitzgerald, SF; Kaneene, JB; Kruger, JM; Nachreiner, RF; Rumbeiha, WK, 1999) |
| "Two patients with malignancy-associated hypercalcemia from bone metastases of breast cancer, accompanied by consciousness disturbance, were treated by a combination therapy of pamidronate and salmon calcitonin." | 3.70 | [Two cases of malignancy-associated hypercalcemia from bone metastases of breast cancer successfully treated with combination therapy using pamidronate and calcitonin]. ( Aoki, T; Kaise, H; Koyanagi, Y; Kusama, M; Matsunaga, T; Nakamura, Y; Nakayama, S; Ota, D, 2000) |
| " Pamidronate (Aredia(TM)) is the most widely evaluated bisphosphonate and is recommended for most patients with multiple myeloma or breast cancer with bone metastases." | 3.70 | Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM). ( Coleman, RE, 2000) |
| "The purpose of this study was to investigate the effects of pamidronate, a second generation bisphosphonate, on the change in calcium homeostasis in patients with tumor-associated hypercalcemia." | 3.69 | Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics. ( Ariyoshi, Y; Hasegawa, H; Niinomi, M; Oiso, Y; Sakiyama, N; Takano, T; Tomita, A; Yamamoto, M, 1994) |
| "25 mmol/L external Ca2+, 200 mumol/L gallium nitrate inhibited PTH release from preparations of primary and uremic hyperparathyroidism by 14% and 22%, respectively." | 3.69 | Effects of the antihypercalcemic drugs gallium nitrate and pamidronate on hormone release of pathologic human parathyroid cells. ( Akerström, G; Gylfe, E; Rastad, J; Ridefelt, P, 1995) |
| "We reviewed our experience with pamidronate in 160 patients with tumour-induced hypercalcemia (TIH) persisting after rehydration, particularly the influence of the dose administered, the tumour type and the presence of bone metastatic involvement on the calcaemic and calciuric response to pamidronate therapy." | 3.69 | Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type. ( Body, JJ; Dumon, JC, 1994) |
| "Intravenous pamidronate disodium has been used successfully in the treatment of malignancy-associated hypercalcemia and Paget's disease of bone." | 3.69 | Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism. ( Graves, L; Tal, A, 1996) |
| " This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome." | 3.69 | Milk-alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism. ( Powers, K; Tal, A, 1996) |
| "Pamidronate (APD) is a drug widely used for the treatment of hypercalcemia of malignancy." | 3.69 | Safety of pamidronate in patients with renal failure and hypercalcemia. ( Flombaum, CD; Machado, CE, 1996) |
| " One of the earliest agents to be investigated, etidronate, is effective in the management of malignant hypercalcemia and, when used orally and intermittently, results in reduced bone loss in osteoporosis." | 3.69 | Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. ( Ashley, S; Hanson, J; Kanis, JA; McCloskey, E; Paterson, AH; Powles, TJ, 1995) |
| "A 65-year-old woman admitted for palliative care of metastatic renal/bladder carcinoma developed symptomatic hypocalcemia nine days following a single dose of pamidronate." | 3.69 | Symptomatic hypocalcemia after intravenous pamidronate. ( Bruera, E; McIntyre, E, 1996) |
| "Autopsy specimens of a bone metastasis from a woman with a primary squamous cell carcinoma of the tongue who developed multiple osteolytic lesions and hypercalcemia and was treated with pamidronate were studied histologically, histochemically, and ultrastructurally." | 3.69 | Effects of bisphosphonate (pamidronate) on bone resorption resulting from metastasis of a squamous cell carcinoma: report of an autopsy case and evaluation of bone resorbing activity in an experimental animal model. ( Hiraga, T; Nakajima, T; Ozawa, H; Takada, M, 1996) |
| "Pamidronate is a second generation bisphosphonate used for treating tumor-induced hypercalcemia and for preventing the development of new bone metastasis." | 3.69 | [Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma]. ( Arima, K; Hioki, T; Kawamura, J; Kise, H; Kobayashi, K; Sugiura, Y; Tochigi, H; Yanagawa, M, 1996) |
| "The response to the bisphosphonate, pamidronate, is reported in a child with osteogenesis imperfecta who had recurrent symptomatic hypercalcaemia after immobilisation following fractures." | 3.69 | Hypercalcaemia in osteogenesis imperfecta treated with pamidronate. ( Ball, RJ; Smith, RA; Wilkinson, H; Williams, CJ, 1997) |
| "Hypercalcemia in a 4-year-old boy with non-Hodgkin lymphoma treated with pamidronate is presented." | 3.69 | Childhood cancer and hypercalcemia: report of a case treated with pamidronate. ( Akyüz, C; Büyükpamukçu, M; Hazar, V; Kutluk, MT; Varan, A, 1997) |
| " The time course study on the antihypercalcemic effect of pamidronate was performed using a rat hypercalcemia model induced by orally administered cholecalciferol." | 3.68 | Effect of pamidronate in a rat hypercalcemia model induced by cholecalciferol. ( Hasegawa, Y; Inukai, T; Noguchi, S; Okada, M, 1992) |
| "Pamidronate (aminopropylidene diphosphonate, APD) is known to be an effective agent in lowering plasma calcium in cancer associated hypercalcaemia and in primary hyperparathyroidism." | 3.68 | [Combination therapy with pamidronate and calcitonin in hypercalcemic crisis caused by primary hyperparathyroidism]. ( Christensen, JH; Kristiansen, JH, 1992) |
| "The effect of lowering ionized calcium on circulating parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP) was assessed in twenty patients with hypercalcemia of malignancy following treatment with Pamidronate Disodium." | 3.68 | Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD). ( Grill, V; Ho, PW; Jerums, G; Martin, TJ; Murray, RM; Pitt, P; Potts, C; Santamaria, JD, 1992) |
| "Nine patients (median age, 81 years) with primary hyperparathyroidism were treated with intravenous infusions of disodium pamidronate (APD), which is a bisphosphonate drug." | 3.68 | Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. ( Jansson, S; Lindstedt, G; Lundberg, PA; Tisell, LE, 1991) |
| "Seventeen patients with malignant hypercalcemia were treated with a combination of a single dose of 3-amino 1-hydroxypropylidene-1-bisphosphonate (APD [also known as AHPrBP or palmidronate disodium]) and salmon calcitonin given as suppositories for 3 days." | 3.68 | Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. ( Burckhardt, P; Jacquet, AF; Thiébaud, D, 1990) |
| "Glucocorticoids may be used as primary treatment when hypercalcemia is due to excessive intestinal calcium absorption (vitamin D intoxication, granulomatous disorders, some lymphomas)." | 2.82 | Hypercalcemia: A Review. ( Shane, E; Walker, MD, 2022) |
| "Pamidronate treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia." | 2.69 | Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. ( Abildgaard, N; Brincker, H; Ford, J; Gimsing, P; Hedenus, M; Kandra, A; Turesson, I; Westin, J, 1998) |
| " In a randomized phase III trial of 377 patients with multiple myeloma, Aredia was administered in a dosage of 90 mg i." | 2.68 | The role of bisphosphonates in the treatment of bone metastases--the U.S. experience. ( Harvey, HA; Lipton, A, 1996) |
| "Hypercalcemia of malignancy (HM) is one of the commonest metabolic complications associated with cancer." | 2.67 | Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. ( Wimalawansa, SJ, 1994) |
| "Pamidronate was given in a single infusion on day 0, the dose of pamidronate adapted to the severity of hypercalcemia." | 2.67 | [Pamidronate in the treatment of tumor-associated hypercalcemia]. ( Bosse, C; Fortelny, A; Gerber, E; Janisch, S; Lenzhofer, R; Marosi, C; Pecherstorfer, M; Rainer, H; Schratzberger, W; Wogritsch, C, 1991) |
| "Thirty-three cancer patients remaining hypercalcemic after a 48-h rehydration period were included and monitored daily until normocalcemia or treatment failure was documented." | 2.66 | Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions. ( Body, JJ; Borkowski, A; Magritte, A; Sculier, JP; Seraj, F, 1989) |
| "Thirty-nine patients with cancer-associated hypercalcaemia were randomly allocated to receive aminohydroxypropylidene diphosphonate (APD), mithramycin, or corticosteroids and salmon calcitonin." | 2.66 | Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. ( Boyle, IT; Cowan, RA; Dryburgh, FJ; Gardner, MD; Jenkins, AS; Ralston, SH, 1985) |
| "There was a significant reduction in pathological fractures and severe bone pain in the APD group, and hypercalcaemia was prevented." | 2.66 | Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. ( Beex, LV; Bijvoet, OL; Cleton, FJ; Elte, JW; Harinck, HI; Hermans, J; Kroon, HM; Neijt, JP; van Holten-Verzantvoort, AT; Vermey, P, 1987) |
| "Hypercalcemia is sustained by an inability of the kidney to deal efficiently with a chronically increased calcium load." | 2.66 | Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. ( Bijvoet, OL; Body, JJ; Elte, JW; Harinck, HI; Neijt, JP; Plantingh, AS; Sleeboom, HP; Wildiers, J, 1987) |
| "Indomethacin was effective in only one of five patients to whom it was given, and EHDP was effective also in only one of five patients." | 2.65 | Comparative study of available medical therapy for hypercalcemia of malignancy. ( Heath, DA; Mundy, GR; Wilkinson, R, 1983) |
| "As hypercalcemia is a serious metabolic complication, a gradual dose reduction should be considered when interruption of high dose denosumab therapy is planned." | 2.61 | Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review. ( Brazeau-Lamontagne, L; Dufresne, J; Huot Daneault, A; Massicotte, MH; Roux, S, 2019) |
| "Williams-Beuren syndrome (WBS) is a rare genetic disorder caused by the deletion of 26-28 genes on chromosome 7." | 2.50 | Importance of dietary calcium and vitamin D in the treatment of hypercalcaemia in Williams-Beuren syndrome. ( Geesing, CL; Hoenderop, JG; Lameris, AL; Schreuder, MF, 2014) |
| "Hypercalcemia has been described as a possible complication of many pediatric malignancies." | 2.45 | Hypercalcemia in pediatric acute megakaryocytic leukemia: case report and review of the literature. ( Ahmed, I; Cushing, B; Qayed, M; Rajpurkar, M; Valentini, RP, 2009) |
| "Pamidronate was given to treat hypercalcemia of unknown etiology." | 2.42 | Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. ( Asif, A; Banerjee, D; Bourgoignie, JJ; Preston, RA; Roth, D; Striker, L, 2003) |
| "Recurrent hypercalcemia is nevertheless difficult to control and antibodies against parathyroid hormone-related protein could be useful for that matter in selected patients who are not in the terminal stage of their disease." | 2.42 | Hypercalcemia of malignancy. ( Body, JJ, 2004) |
| "Zoledronic acid has also received the broadest regulatory approval of any bisphosphonate and can be used to treat HCM or bone lesions secondary to multiple myeloma and a wide variety of solid tumors, including breast, prostate, and lung cancers." | 2.42 | Safety and convenience of a 15-minute infusion of zoledronic acid. ( Berenson, J; Hirschberg, R, 2004) |
| "Hypercalcemia of malignancy (HCM) is a potentially life-threatening complication of cancer resulting from increased bone resorption by osteoclasts." | 2.41 | Treatment of hypercalcemia of malignancy with bisphosphonates. ( Berenson, JR, 2002) |
| "Myelomatosis is associated with considerable skeletal morbidity, particularly bone pain and fractures." | 2.41 | Bisphosphonates in multiple myeloma. ( Kanis, JA; McCloskey, EV, 2000) |
| "Specific treatment of cancer remains essential to prevent TIH relapse." | 2.41 | [Tumor-induced hypercalcemia. Review of bisphosphonate treatment]. ( Lortholary, A, 2001) |
| "Patients with breast cancer associated solely with osseous metastasis may live for a number of years." | 2.41 | Treatment of metastatic bone disease in breast cancer: bisphosphonates. ( Bastert, G; Diel, IJ; Solomayer, EF, 2000) |
| "Pamidronate (APD) is a potent inhibitor of bone resorption that is useful in the management of patients with osteolytic bone metastases from breast cancer or multiple myeloma, tumour-induced hypercalcaemia or Paget's disease of bone." | 2.40 | Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. ( Coukell, AJ; Markham, A, 1998) |
| "We present a case of undifferentiated pancreatic cancer associated with humoral hypercalcemia of malignancy (HHM) in which parathyroid hormone-related protein (PTH-rP) is identified as the causative factor of hypercalcemia." | 2.40 | Undifferentiated pancreatic cancer associated with humoral hypercalcemia of malignancy. ( Higuchi, T; Kakizaki, S; Kitazawa, R; Mori, M; Nagamine, T; Ohya, N; Takagi, H; Takayama, H; Yoshinaga, T, 1998) |
| "This is particularly true in multiple myeloma (MM), where bone involvement markedly influences the quality of life of patients." | 2.40 | The role of bisphosphonates for the treatment of bone disease in multiple myeloma. ( Musto, P, 1998) |
| " Review of the published literature suggests that a clinically relevant dose-response relationship exists in the dose range 30-60 mg; most hypercalcemic patients will achieve normocalcemia with a dose of 60 mg pamidronate or more." | 2.39 | Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects? ( Thürlimann, B, 1994) |
| "Treatment of cancer associated hypercalcaemia is based on an initial phase of volume repletion with isotonic saline, followed by drug treatment to inhibit bone resorption." | 2.39 | Pathogenesis and management of cancer associated hypercalcaemia. ( Ralston, SH, 1994) |
| "The variability of different breast cancers in the susceptibility to metastatic bone disease is poorly understood." | 2.39 | Rationale for the use of bisphosphonates in breast cancer. ( Kanis, JA, 1996) |
| " Long term use of low-dose pamidronate in conjunction with conventional antiosteoporotic therapy may halt bone loss in steroid-induced and idiopathic osteoporosis." | 2.38 | Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. ( Fitton, A; McTavish, D, 1991) |
| "Congenital mesoblastic nephroma is a rare pediatric renal tumor and has been reported in patients presenting with palpable abdominal mass, arterial hypertension, hematuria, polyuria, or hypercalcemia." | 1.72 | Severe neonatal hypercalcemia revealing congenital mesoblastic nephroma: A case report and management of neonatal hypercalcemia: Severe neonatal hypercalcemia revealing congenital mesoblastic nephroma. ( Bacchetta, J; Bordet, F; Dijoud, F; Duncan, A; Mure, PY; Pracros, JP; Tanné, C, 2022) |
| "This study demonstrates that Pam is effective and safe for treating PTHRH, while ensuring close laboratory monitoring of calcium and phosphorus metabolism." | 1.62 | Efficacy and Safety of Intravenous Pamidronate for Parathyroid Hormone-dependent Hypercalcemia in Hospitalized Patients. ( Barzilay-Yoseph, L; Klein, N; Ramaty, E; Rosenblum, RC; Rotman-Pikielny, P; Twito, O, 2021) |
| "BACKGROUND Hypercalcemia is a common complication in the intensive care unit (ICU)." | 1.48 | Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report. ( El Madhoun, I; El Zeer, HS; Khatib, M; Mahmoud, S; Mitwally, H, 2018) |
| "He had a prior diagnosis of autism and his mother had consulted an alternative therapist who had recommended many supplements, including calcium and vitamin D." | 1.43 | Severe hypercalcaemia in a child secondary to use of alternative therapies. ( Boyd, C; Moodambail, A, 2016) |
| "Hypercalcemia is a common complication of malignancy and portends a worse prognosis." | 1.40 | Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy. ( Pani, A; Reagan, P; Rosner, MH, 2014) |
| "Primary hyperparathyroidism is characterised by high parathyroid hormone (PTH) levels and concomitant hypercalcaemia." | 1.40 | Exceptional localisation of an ectopic parathyroid adenoma at the level of the hyoid bone. ( Musters, L; Smit, C; van Ginhoven, TM, 2014) |
| "Pamidronate has a beneficial effect in those patients with IIH where glucocorticoids and furosemide fail to meet the expectations." | 1.39 | Intravenous pamidronate in the treatment of severe idiopathic infantile hypercalcemia. ( Bayer, M; Cerna, L; Konrad, M; Kutilek, S; Schlingmann, KP; Skalova, S, 2013) |
| "Hypercalcemia is mainly caused by bone resorption due to either secretion of cytokines including parathyroid hormone-related protein (PTHrP) or bone metastases." | 1.38 | Impact of chemotherapy on hypercalcemia in breast and lung cancer patients. ( Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB, 2012) |
| "Uterine leiomyomas are the most common pelvic tumor, and a frequent indication of the need for gynecologic surgery." | 1.37 | Severe hypercalcemia associated with uterine leiomyoma in pregnancy. ( Richardson, M; Spruill, L; Sullivan, S; Tarnawa, E; Underwood, P, 2011) |
| "Subcutaneous fat necrosis of the newborn (SCFN) is a panniculitis that develops in fatty areas during the first weeks of life after foetal distress or perinatal complications." | 1.35 | Effectiveness of pamidronate in severe neonatal hypercalcemia caused by subcutaneous fat necrosis: a case report. ( Bollani, L; Cabano, R; Del Forno, C; Lombardi, G; Stronati, M, 2009) |
| "For patients with HCM who do not achieve a response from bisphosphonates, or for those who need repeated dosing more often than expected, changing to a different drug class could be an alternative." | 1.35 | A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm. ( Linneman, T; McMahan, J, 2009) |
| "Hypercalcemia is rare and when it is diagnosed, primary hyperparathyroidism should be ruled out." | 1.35 | [Paget's disease and hypercalcemia: coincidence or causal relationship?]. ( Altman, A; Green, I, 2009) |
| "Tumor-induced hypercalcemia is a frequent complication of advanced cancers, but it has been rarely reported in patients with sarcoma." | 1.34 | Tumor induced hypercalcemia in a patient with mediastinal synovial sarcoma. ( Badiei, Z; Hiradfar, M; Vakili, R; Zabolinejad, N, 2007) |
| "Pamidronate was well tolerated apart from one case of multifactorial renal failure." | 1.33 | Hypercalcemia and childhood cancer: a 7-year experience. ( Aerts, I; Chevret, L; Doz, F; Fattet, S; Garabedian, M; Kerdudo, C; Michon, J; Orbach, D; Pacquement, H, 2005) |
| "Hypercalcemia was induced either by sc inoculation of syngeneic colon (C-26) adenocarcinoma cells or by sc injection of high-dose recombinant PTHrP (0." | 1.33 | The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. ( Adamu, S; Asuncion, F; Capparelli, C; Dunstan, CR; Geng, Z; Grisanti, M; Kostenuik, PJ; Morony, S; Starnes, C; Tan, HL; Warmington, K; Weimann, B, 2005) |
| "Treatments of hypercalcemia have included hydration, furosemide and corticosteroids." | 1.33 | Pamidronate: Treatment for severe hypercalcemia in neonatal subcutaneous fat necrosis. ( Alos, N; Chabot, G; Eugène, D; Fillion, M; Kokta, V; Powell, J, 2006) |
| "The frequency of bone metastases of breast cancer has been reported to be 65-75% of all breast cancer patients, and, in autopsy example at Shikoku Cancer Center, metastasis was recognized to be 74." | 1.33 | [The incidence and management of bone metastasis from breast cancer]. ( Fujiuchi, N; Ookubo, K; Saeki, T; Takeuchi, H, 2006) |
| "A patient with multiple myeloma who developed hypercalcemia during three different stages of his disease, with a different hypercalcemic agent elevated in his serum on each occasion, is described." | 1.32 | Hypercalcemia due to sun exposure in a patient with multiple myeloma and elevated parathyroid hormone-related protein. ( Bergi-Stamatelou, M; Karga, H; Papapetrou, PD; Thanou, S, 2003) |
| "The pamidronate dose was increased to 60 mg once a week and was well tolerated." | 1.32 | Pamidronate in a girl with chronic renal insufficiency dependent on parenteral nutrition. ( Chesney, RW; Duke, JL; Frizzell, NK; Hak, EB; Jones, DP, 2003) |
| "By inhibiting bone resorption, bisphosphonate administration caused transient normalization of calcemia, associated with improved FIM, at a significantly higher level than in untreated patients (+16." | 1.32 | A single bisphosphonate infusion is associated with improved functional capacity in elderly subjects with primary hyperparathyroidism. ( Ammann, P; Herter-Clavel, C; Lubrano, A; Rizzoli, R, 2003) |
| "The use of pamidronate for treatment of hypercalcemia and chronic conditions that affect normal bone growth is increasing in children." | 1.32 | Pamidronate treatment for hypercalcemia in an infant receiving parenteral nutrition. ( Bryowsky, JJ; Bugnitz, MC; Hak, EB, 2004) |
| "Zoledronic acid (6i) has thus been selected for clinical development under the registered trade name Zometa." | 1.31 | Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). ( Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L, 2002) |
| "Hypercalcemia is a serious complication of malignancies, but it is uncommon in acute leukemia." | 1.31 | Megakaryoblastic transformation of polycythemia vera with hypercalcemia. ( Iwasaki, H; Kurosawa, M, 2002) |
| "Although treatment of hypercalcemia with pamidronate is palliative, it is effective against the deterioration of quality of life." | 1.31 | [Treatment of hypercalcemia of malignancy with pamidronate in a patient with advanced recurrent oral cancer]. ( Hashitani, S; Matsushita, Y; Nishimura, N; Noguchi, K; Takaoka, K; Urade, M, 2002) |
| "Treatment with pamidronate (Aredia) was successful and reduced the serum calcium to normal values." | 1.31 | [Immobilization hypercalcemia as a complication of polyneuropathy]. ( Block, F; Brandenburg, VM; Dietrich, CG; Riehl, J, 2000) |
| "We report on a patient with parathyroid carcinoma with hypercalcaemia and pulmonary metastases, treated with pamidronate and radiotherapy and later with surgery." | 1.31 | Positive effect of radiotherapy and surgery on hormonally active pulmonary metastases of primary parathyroid carcinoma. ( Boquist, L; Kristoffersson, A; Rasmuson, T, 2000) |
| "Hypercalcemia was defined as a serum Ca concentration higher than 11 mg/dl of the correction for serum albumin concentration." | 1.31 | Hypercalcemia in patients with oral squamous cell carcinoma. ( Iwase, M; Kakuta, S; Kurachi, Y; Nagumo, M; Nakamura-Mitsuhashi, M; Sakamaki, H, 2001) |
| "We report a male patient with advanced AIDS who developed hypercalcemia 2 weeks after institution of rhGH therapy." | 1.30 | Hypercalcemia in an AIDS patient treated with growth hormone. ( Hartzband, P; Lally, M; Sakoulas, G; Tritos, NA; Wanke, C, 1997) |
| "Tumor-induced osteolysis is essentially mediated by the osteoclasts whose number and activity appear to be stimulated under the influence of tumor secretory products." | 1.30 | [Bone metastases: pathogenesis and treatment with diphosphonates]. ( Body, JJ, 1997) |
| "The hypercalcemia was refractory to extensive hydration and calcitonin, but was ameliorated by pamidronate." | 1.30 | Hypercalcemia in an euthyroid patient with secondary hypoadrenalism and diabetes insipidus due to hypothalamic tumor. ( Demura, H; Hotta, M; Sato, K; Shibasaki, T, 1998) |
| "In those patients in whom systemic anti-cancer therapy is available, treatment with APD improves survival, but in all other patients the primary aim of treatment should be symptom control." | 1.29 | Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). ( A'Hern, RP; Hardy, JR; Ling, PJ, 1995) |
| "Pamidronate therapy was effective in restoring serum calcium to normal." | 1.29 | Hypercalcaemia in primary oxalosis: role of increased bone resorption and effects of treatment with pamidronate. ( Barnes, ND; Compston, JE; Grant, J; Jamieson, N; Noble-Jamieson, G; Yamaguchi, K, 1995) |
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 1.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| "Pamidronate was given to 10 patients with end stage renal failure who had become symptomatically hypercalcaemic due to the use of calcium based phosphate binders and alphacalcidol." | 1.29 | Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure. ( Davenport, A; Goel, S; Mackenzie, JC, 1993) |
| "Breast cancers were more common in group N, squamous cell cancers predominated in group E (p < 0." | 1.29 | Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. ( Baumgartner, G; Blind, E; Pecherstorfer, M; Raue, F; Schilling, T; Ziegler, R; Zimmer-Roth, I, 1994) |
| "Parathyroid carcinoma is rare and the associated hypercalcaemia is often resistant to all treatment." | 1.29 | Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate. ( Braatvedt, GD; Corrall, RJ; Newrick, PG; Sheffield, E; Webb, AJ, 1994) |
| "Primary hyperparathyroidism is usually associated with normal or elevated serum 1,25-dihydroxyvitamin D [1,25(OH)2D] levels." | 1.29 | Inhibition of 1,25(OH)2D production by hypercalcemia in osteitis fibrosa cystica: influence on parathyroid hormone secretion and hungry bone disease. ( Brossard, JH; D'Amour, P; Garon, J; Gascon-Barré, M; Lepage, R, 1993) |
| "A 57-year-old man with lung squamous cell carcinoma revealed hypercalcemia, hypophosphoremia, elevation of nephrogenous cAMP and metabolic alkalosis." | 1.29 | A case of squamous cell lung carcinoma with high concentration of parathyroid hormone-related peptide in serum and pleural effusion presenting hypercalcemia. ( Haji, M; Hara, N; Ichinose, Y; Iguchi, H; Katakami, H; Nawata, H; Nishi, Y; Ohta, M; Tanaka, S, 1993) |
| "Pamidronate treatment resulted in a brisk reduction in plasma calcium concentration." | 1.29 | Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. ( Davies, M; Marks, JS; Mawer, EB; Selby, PL, 1995) |
| " Patients received, on average, 30 mg less pamidronate than that given in the manufacturer's dosing schedule." | 1.29 | An audit of the management of malignant hypercalcaemia. ( Dodwell, DJ; Gerrard, GE; Overend, MA; Vail, A; Watters, J, 1996) |
| "Pamidronate has been demonstrated to be an effective agent in the treatment of cancer-associated hypercalcaemia." | 1.28 | A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia. ( Boyle, IT; Cowan, RA; Dryburgh, FJ; Fraser, WD; Gallacher, SJ; Logue, FC; Ralston, SH, 1991) |
| " The author discusses the administration, dosage and side effects, and results of current studies." | 1.28 | Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy. ( Coleman, RE, 1991) |
| "The rat Walker carcinosarcoma 256 is an animal model for humoral hypercalcaemia of malignancy (HHM)." | 1.28 | Relative role of bone and kidney in the hypercalcaemia associated with the rat Walker carcinosarcoma 256. ( Esbrit, P; Hurtado, J; Rapado, A, 1991) |
| "Life expectancy is poor in cancer-associated hypercalcemia even in patients who are actively treated." | 1.28 | Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. ( Boyle, IT; Campbell, J; Gallacher, SJ; Patel, U; Ralston, SH, 1990) |
| "A 10-year-old boy with leukaemia-associated hypercalcaemia was treated with aminohydroxypropylidene biphosphonate (AHPrBP previously APD) in a total dosage of 60 mg over 5 days, when the condition failed to respond to rehydration and frusemide and no sustained effect was produced by haemodialysis with a calcium (Ca)-free dialysate." | 1.28 | Leukaemia-associated hypercalcaemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate. ( Boudailliez, BR; Kremp, O; Pautard, BJ; Piussan, CX; Sebert, JL, 1990) |
| "Retreatment with pamidronate again resulted in normocalcaemia." | 1.28 | Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate. ( Allam, BF; Boyce, BF; Boyle, IT; Dryburgh, FJ; Gallacher, SJ; Logue, FC; Ralston, SH, 1990) |
| "While patients with renal osteodystrophy react favorably to supplementation of active vitamin D metabolites to prevent or reverse renal osteodystrophy, the use of these drugs is bound to result in greater hypercalcemia in those patients who are already hypercalcemic." | 1.28 | No effect of APD (amino hydroxypropylidene bisphosphonate) on hypercalcemia in patients with renal osteodystrophy. ( de bos Kuil, RJ; Dorhout Mees, EJ; Duursma, SA; Hené, RJ; Raymakers, JA; Visser, WJ, 1990) |
| "Malignant hypercalcemia is caused by both increased bone resorption and enhanced tubular reabsorption of calcium." | 1.28 | Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone. ( Burckhardt, P; Jaeger, P; Thiebaud, D, 1990) |
| "There were seven patients with breast cancer, eight with lung cancer, and ten with a variety of other cancers." | 1.28 | Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia. ( Cantwell, BM; Carmichael, J; Harris, AL; Mannix, KA, 1989) |
| "Eight patients with cancer associated hypercalcaemia were treated with the combination of aminohydroxypropylidene diphosphonate and salmon calcitonin for six days." | 1.27 | Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin. ( Alzaid, AA; Boyle, IT; Gardner, MD; Ralston, SH, 1986) |
| " In order to establish a dose-response in humans, patients were divided into four groups receiving 30 mg, 45 mg, 60 mg, or 90 mg, respectively, as a 24-hour infusion." | 1.27 | Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. ( Burckhardt, P; Jacquet, AF; Jaeger, P; Thiébaud, D, 1988) |
| "The hypercalcemia was corrected by a single intravenous dose of (3-amino-1-hydroxypropylidene)-1,1-diphosphonate (15 mg), allowing parathyroidectomy to be performed electively and on a well patient." | 1.27 | Aminohydroxypropylidene diphosphonate treatment of hypercalcemic crisis due to primary hyperparathyroidism. ( Evans, RA, 1987) |
| " AHPrBP was given as two-hour daily infusions for three days, and three different patients were treated at each of the six following dosage levels: 0." | 1.27 | Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia. ( Body, JJ; Borkowski, A; Klastersky, J; Pot, M; Sculier, JP, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 47 (15.11) | 18.7374 |
| 1990's | 146 (46.95) | 18.2507 |
| 2000's | 77 (24.76) | 29.6817 |
| 2010's | 35 (11.25) | 24.3611 |
| 2020's | 6 (1.93) | 2.80 |
| Authors | Studies |
|---|---|
| Widler, L | 1 |
| Jaeggi, KA | 1 |
| Glatt, M | 1 |
| Müller, K | 1 |
| Bachmann, R | 1 |
| Bisping, M | 1 |
| Born, AR | 1 |
| Cortesi, R | 1 |
| Guiglia, G | 1 |
| Jeker, H | 1 |
| Klein, R | 1 |
| Ramseier, U | 1 |
| Schmid, J | 1 |
| Schreiber, G | 1 |
| Seltenmeyer, Y | 1 |
| Green, JR | 1 |
| Zubair Ullah, HM | 1 |
| Surya, A | 1 |
| Morley, N | 1 |
| Ahmad, S | 1 |
| Tanné, C | 1 |
| Pracros, JP | 1 |
| Dijoud, F | 1 |
| Mure, PY | 1 |
| Bordet, F | 1 |
| Duncan, A | 1 |
| Bacchetta, J | 1 |
| Shulman, R | 1 |
| Geara, AS | 1 |
| Berns, JS | 1 |
| Walker, MD | 1 |
| Shane, E | 1 |
| Norman, SJ | 1 |
| Reeves, DJ | 1 |
| Saum, LM | 1 |
| Satyarengga, M | 1 |
| Silver, KD | 1 |
| Rosenblum, RC | 1 |
| Twito, O | 1 |
| Barzilay-Yoseph, L | 1 |
| Ramaty, E | 1 |
| Klein, N | 1 |
| Rotman-Pikielny, P | 1 |
| Arif, H | 1 |
| Beg, M | 1 |
| Zahid, S | 1 |
| Sial, M | 1 |
| Talwar, A | 1 |
| Christou, A | 1 |
| Babich, M | 1 |
| Basok, AB | 1 |
| Rogachev, B | 1 |
| Haviv, YS | 1 |
| Vorobiov, M | 1 |
| Ellis, S | 1 |
| Tsiopanis, G | 1 |
| Lad, T | 1 |
| Mahmoud, S | 1 |
| Mitwally, H | 1 |
| El Zeer, HS | 1 |
| El Madhoun, I | 1 |
| Khatib, M | 1 |
| Baştuğ, F | 1 |
| Nalçacıoğlu, H | 1 |
| Baş, VN | 1 |
| Tekatlı-Çelik, B | 1 |
| Çetinkaya, H | 1 |
| Yel, S | 1 |
| Demir, K | 1 |
| Döneray, H | 1 |
| Kara, C | 1 |
| Atay, Z | 1 |
| Çetinkaya, S | 1 |
| Çayır, A | 1 |
| Anık, A | 1 |
| Eren, E | 1 |
| Uçaktürk, A | 1 |
| Can Yılmaz, G | 1 |
| Törel Ergür, A | 1 |
| Kendirci, M | 1 |
| Aycan, Z | 1 |
| Bereket, A | 1 |
| Aydın, M | 1 |
| Orbak, Z | 1 |
| Özkan, B | 1 |
| Kim, S | 1 |
| Roux, S | 1 |
| Massicotte, MH | 1 |
| Huot Daneault, A | 1 |
| Brazeau-Lamontagne, L | 1 |
| Dufresne, J | 1 |
| Haykal, T | 1 |
| Sundus, S | 1 |
| Bachuwa, G | 1 |
| Danish, R | 1 |
| Arango, ML | 1 |
| Shah, AN | 1 |
| Hooman, N | 1 |
| Skalova, S | 1 |
| Cerna, L | 1 |
| Bayer, M | 1 |
| Kutilek, S | 1 |
| Konrad, M | 1 |
| Schlingmann, KP | 1 |
| Reagan, P | 1 |
| Pani, A | 1 |
| Rosner, MH | 1 |
| Boumans, D | 1 |
| de Vries, PA | 1 |
| Rikken, NE | 1 |
| Laverman, GD | 1 |
| Guarino, S | 1 |
| Marzuillo, P | 1 |
| Apicella, A | 1 |
| Annicchiarico Petruzzelli, L | 1 |
| La Manna, A | 1 |
| Lameris, AL | 1 |
| Geesing, CL | 1 |
| Hoenderop, JG | 1 |
| Schreuder, MF | 1 |
| Musters, L | 1 |
| van Ginhoven, TM | 1 |
| Smit, C | 1 |
| Pittaway, JF | 1 |
| Srirangalingam, U | 1 |
| Hanson, PL | 1 |
| Jones, P | 1 |
| Drake, WM | 1 |
| Ismail, J | 1 |
| Wright, JD | 1 |
| Tergas, AI | 1 |
| Ananth, CV | 1 |
| Burke, WM | 1 |
| Hou, JY | 1 |
| Chen, L | 1 |
| Neugut, AI | 1 |
| Richards, CA | 1 |
| Hershman, DL | 1 |
| Liao, M | 1 |
| Magcalas, P | 1 |
| Hopkins-Braddock, P | 1 |
| Patnaik, S | 1 |
| Lai, YK | 1 |
| Boyd, C | 1 |
| Moodambail, A | 1 |
| Lombardi, G | 1 |
| Cabano, R | 1 |
| Bollani, L | 1 |
| Del Forno, C | 1 |
| Stronati, M | 1 |
| Lombet, J | 1 |
| Auron, A | 1 |
| Tal, L | 1 |
| Srivastava, T | 1 |
| Alon, US | 1 |
| Pao, VY | 1 |
| Chang, S | 1 |
| Shoback, DM | 1 |
| Bikle, DD | 1 |
| Czosnowski, LM | 1 |
| Hudson, JQ | 1 |
| Canada, RB | 1 |
| Qayed, M | 1 |
| Ahmed, I | 1 |
| Valentini, RP | 1 |
| Cushing, B | 1 |
| Rajpurkar, M | 1 |
| Labossiere, R | 1 |
| Hintzke, C | 1 |
| Ileana, S | 1 |
| McMahan, J | 1 |
| Linneman, T | 1 |
| Green, I | 1 |
| Altman, A | 1 |
| Bergstein, KR | 1 |
| Jacobsen, RB | 1 |
| Jacobsen, BB | 1 |
| Christesen, HT | 1 |
| ten Dam, MA | 1 |
| Hilbrands, LB | 1 |
| Wetzels, JF | 1 |
| Whitney, JL | 1 |
| Barrs, VR | 1 |
| Wilkinson, MR | 1 |
| Briscoe, KA | 1 |
| Beatty, JA | 1 |
| Tarnawa, E | 1 |
| Sullivan, S | 1 |
| Underwood, P | 1 |
| Richardson, M | 1 |
| Spruill, L | 1 |
| Ludwig, H | 1 |
| Zojer, N | 1 |
| Sangun, O | 1 |
| Dundar, BN | 1 |
| Erdogan, E | 1 |
| Legrand, SB | 1 |
| Hoi, WH | 1 |
| Leow, MK | 1 |
| Sule, A | 1 |
| Lee, HY | 1 |
| Mmed, TA | 1 |
| Tay, JC | 1 |
| Shimizu, H | 1 |
| Monden, T | 1 |
| Tomotsune, T | 1 |
| Nakatani, Y | 1 |
| Domeki, N | 1 |
| Matsumura, M | 1 |
| Jojima, T | 1 |
| Kawagoe, Y | 1 |
| Kasai, K | 1 |
| Hassan, BA | 1 |
| Yusoff, ZB | 1 |
| Hassali, MA | 1 |
| Othman, SB | 1 |
| Weiderpass, E | 1 |
| Murphy, L | 1 |
| McCarthy, J | 1 |
| McCrate, F | 1 |
| Laing, K | 1 |
| Powell, E | 1 |
| Seal, M | 1 |
| Edwards, S | 1 |
| Kurosawa, M | 1 |
| Iwasaki, H | 1 |
| Major, P | 2 |
| Nishimura, N | 1 |
| Matsushita, Y | 1 |
| Takaoka, K | 1 |
| Hashitani, S | 1 |
| Noguchi, K | 1 |
| Urade, M | 1 |
| Major, PP | 1 |
| Cook, R | 1 |
| Alborzi, F | 1 |
| Leibowitz, AB | 1 |
| Berenson, JR | 2 |
| Papapetrou, PD | 1 |
| Bergi-Stamatelou, M | 1 |
| Karga, H | 1 |
| Thanou, S | 1 |
| Mathur, M | 1 |
| Sykes, JA | 1 |
| Saxena, VR | 1 |
| Rao, SP | 1 |
| Goldman, GM | 1 |
| Duke, JL | 1 |
| Jones, DP | 1 |
| Frizzell, NK | 1 |
| Chesney, RW | 1 |
| Hak, EB | 2 |
| Torregrosa, JV | 1 |
| Moreno, A | 1 |
| Mas, M | 1 |
| Ybarra, J | 1 |
| Fuster, D | 1 |
| Banerjee, D | 1 |
| Asif, A | 1 |
| Striker, L | 1 |
| Preston, RA | 1 |
| Bourgoignie, JJ | 1 |
| Roth, D | 1 |
| Pecherstorfer, M | 5 |
| Steinhauer, EU | 1 |
| Rizzoli, R | 3 |
| Wetterwald, M | 1 |
| Bergström, B | 1 |
| Duncan, AR | 1 |
| Kato, A | 1 |
| Shinozaki, S | 1 |
| Goga, T | 1 |
| Hishida, A | 1 |
| Musto, P | 2 |
| Falcone, A | 1 |
| Sanpaolo, G | 1 |
| Bodenizza, C | 1 |
| Cascavilla, N | 1 |
| Melillo, L | 1 |
| Scalzulli, PR | 1 |
| Dell'Olio, M | 1 |
| La Sala, A | 1 |
| Mantuano, S | 1 |
| Nobile, M | 1 |
| Carella, AM | 1 |
| Lu, KC | 1 |
| Yeung, LK | 1 |
| Lin, SH | 2 |
| Lin, YF | 1 |
| Chu, P | 1 |
| Atula, ST | 1 |
| Tähtelä, RK | 1 |
| Nevalainen, JI | 1 |
| Pylkkänen, LH | 1 |
| Ezgu, FS | 1 |
| Buyan, N | 1 |
| Gündüz, M | 1 |
| Tümer, L | 1 |
| Okur, I | 1 |
| Hasanoglu, A | 1 |
| Caldwell, JW | 1 |
| Arsura, EL | 1 |
| Kilgore, WB | 1 |
| Reddy, CM | 1 |
| Johnson, RH | 1 |
| Body, JJ | 16 |
| Ammann, P | 2 |
| Herter-Clavel, C | 1 |
| Lubrano, A | 1 |
| Wenzel, C | 1 |
| Bartsch, R | 1 |
| Hussian, D | 1 |
| Pluschnig, U | 1 |
| Locker, GJ | 1 |
| Sevelda, U | 1 |
| Zielinski, CC | 1 |
| Steger, GG | 1 |
| Berenson, J | 1 |
| Hirschberg, R | 1 |
| Waller, S | 1 |
| Kurzawinski, T | 1 |
| Spitz, L | 1 |
| Thakker, R | 1 |
| Cranston, T | 1 |
| Pearce, S | 1 |
| Cheetham, T | 1 |
| van't Hoff, WG | 1 |
| Bryowsky, JJ | 1 |
| Bugnitz, MC | 1 |
| Oliveri, B | 1 |
| Mastaglia, SR | 1 |
| Mautalen, C | 1 |
| Gravano, JC | 1 |
| Pardo Argerich, L | 1 |
| Díaz, C | 1 |
| Soutelo, MJ | 1 |
| Quiroga, L | 1 |
| Palmer, L | 1 |
| Lutfi, R | 1 |
| Cagle, AP | 1 |
| Waguespack, SG | 1 |
| Buckingham, BA | 1 |
| Shankar, RR | 1 |
| Dimeglio, LA | 1 |
| Jansson, S | 3 |
| Morgan, E | 1 |
| Kerdudo, C | 2 |
| Aerts, I | 2 |
| Fattet, S | 2 |
| Chevret, L | 2 |
| Pacquement, H | 2 |
| Doz, F | 2 |
| Michon, J | 2 |
| Garabedian, M | 2 |
| Orbach, D | 2 |
| Morony, S | 1 |
| Warmington, K | 1 |
| Adamu, S | 1 |
| Asuncion, F | 1 |
| Geng, Z | 1 |
| Grisanti, M | 1 |
| Tan, HL | 1 |
| Capparelli, C | 1 |
| Starnes, C | 1 |
| Weimann, B | 1 |
| Dunstan, CR | 1 |
| Kostenuik, PJ | 1 |
| Balla, J | 1 |
| Lugassy, G | 1 |
| Waterfield, KE | 1 |
| Lee, MA | 1 |
| Regnard, CF | 1 |
| Duque, G | 1 |
| Segal, R | 1 |
| Wise, F | 1 |
| Bianco, J | 1 |
| Tavil, B | 1 |
| Sipahi, T | 1 |
| Kara, A | 1 |
| Pastor-Zuazaga, D | 1 |
| Garatea-Crelgo, J | 1 |
| Martino-Gorbea, R | 1 |
| Etayo-Pérez, A | 1 |
| Sebastián-López, C | 1 |
| Klomp, CM | 1 |
| van den Broek, MW | 1 |
| Buijs, J | 1 |
| Beekman, R | 1 |
| Alos, N | 1 |
| Eugène, D | 1 |
| Fillion, M | 1 |
| Powell, J | 1 |
| Kokta, V | 1 |
| Chabot, G | 1 |
| Cheng, CJ | 1 |
| Chou, CH | 1 |
| Diaz-Borjon, A | 1 |
| Seyler, TM | 1 |
| Chen, NL | 1 |
| Lim, SS | 1 |
| Saeki, T | 1 |
| Ookubo, K | 1 |
| Takeuchi, H | 1 |
| Fujiuchi, N | 1 |
| Trimarchi, H | 1 |
| Lombi, F | 1 |
| Forrester, M | 1 |
| Elizondo, C | 1 |
| Sawinski, D | 1 |
| Pereyra, H | 1 |
| Freixas, E | 1 |
| Culbert, EC | 1 |
| Schfirin, BS | 1 |
| Griz, L | 1 |
| Colares, V | 1 |
| Bandeira, F | 1 |
| Beckers, MM | 1 |
| Slee, PH | 1 |
| Frein, D | 1 |
| Lavigne, C | 1 |
| Josselin, N | 1 |
| Foussard, C | 1 |
| Sivova, N | 1 |
| Moles, MP | 1 |
| Berrut, G | 1 |
| Manouras, A | 1 |
| Toutouzas, KG | 1 |
| Markogiannakis, H | 1 |
| Lagoudianakis, E | 1 |
| Papadima, A | 1 |
| Antonakis, PT | 1 |
| Kafiri, G | 1 |
| Bramis, I | 1 |
| Vakili, R | 1 |
| Hiradfar, M | 1 |
| Zabolinejad, N | 1 |
| Badiei, Z | 1 |
| Chatterjee, M | 1 |
| Speiser, PW | 1 |
| Sleeboom, HP | 4 |
| Bijvoet, OL | 7 |
| van Oosterom, AT | 2 |
| Gleed, JH | 2 |
| O'Riordan, JL | 2 |
| Mundy, GR | 3 |
| Wilkinson, R | 1 |
| Heath, DA | 2 |
| Tubiana-Hulin, M | 1 |
| de Vernejoul, MC | 1 |
| Brière, M | 1 |
| Miravet, L | 1 |
| Clavel, B | 1 |
| Delmas, PD | 3 |
| Meunier, PJ | 1 |
| Schürer, CC | 1 |
| Peters, U | 1 |
| Fischer, JT | 1 |
| van Breukelen, FJ | 1 |
| Frijlink, WB | 1 |
| Mulder, H | 1 |
| Thürlimann, B | 2 |
| Purohit, OP | 2 |
| Radstone, CR | 1 |
| Anthony, C | 1 |
| Kanis, JA | 6 |
| Coleman, RE | 6 |
| Ling, PJ | 1 |
| A'Hern, RP | 1 |
| Hardy, JR | 1 |
| Macro, M | 1 |
| Bouvard, G | 1 |
| Le Gangneux, E | 1 |
| Colin, T | 1 |
| Loyau, G | 1 |
| Oiso, Y | 1 |
| Tomita, A | 1 |
| Hasegawa, H | 1 |
| Ariyoshi, Y | 1 |
| Niinomi, M | 1 |
| Yamamoto, M | 1 |
| Takano, T | 1 |
| Sakiyama, N | 1 |
| Solomon, CG | 1 |
| Dluhy, RG | 1 |
| Tamion, F | 1 |
| Bonmarchand, F | 1 |
| Girault, C | 1 |
| Chevron, V | 1 |
| Leroy, J | 1 |
| Yamaguchi, K | 1 |
| Grant, J | 1 |
| Noble-Jamieson, G | 1 |
| Jamieson, N | 1 |
| Barnes, ND | 1 |
| Compston, JE | 1 |
| Azuma, Y | 1 |
| Sato, H | 1 |
| Oue, Y | 1 |
| Okabe, K | 1 |
| Ohta, T | 1 |
| Tsuchimoto, M | 1 |
| Kiyoki, M | 1 |
| Ridefelt, P | 1 |
| Gylfe, E | 1 |
| Akerström, G | 1 |
| Rastad, J | 1 |
| Wimalawansa, SJ | 2 |
| Anand, A | 1 |
| Anand, N | 1 |
| Sato, K | 2 |
| Imaki, T | 1 |
| Toraya, S | 1 |
| Demura, H | 2 |
| Tanaka, M | 1 |
| Kasajima, T | 1 |
| Takeuchi, A | 1 |
| Kobayashi, T | 1 |
| Walls, J | 1 |
| Ratcliffe, WA | 1 |
| Howell, A | 4 |
| Bundred, NJ | 1 |
| Budayr, AA | 1 |
| Zysset, E | 1 |
| Jenzer, A | 1 |
| Thiébaud, D | 11 |
| Jaquet-Müller, F | 1 |
| Bonjour, JP | 1 |
| Gertz, B | 1 |
| Burckhardt, P | 10 |
| Gucalp, R | 2 |
| Theriault, R | 2 |
| Gill, I | 1 |
| Madajewicz, S | 1 |
| Chapman, R | 2 |
| Navari, R | 1 |
| Ahmann, F | 1 |
| Zelenakas, K | 1 |
| Heffernan, M | 3 |
| Knight, RD | 4 |
| Dumon, JC | 4 |
| Kotzmann, H | 1 |
| Svoboda, T | 1 |
| Bernecker, P | 1 |
| Clodi, M | 1 |
| Woloszczuk, W | 1 |
| Niederle, B | 1 |
| Waldhäusl, W | 1 |
| Luger, A | 1 |
| Gurney, H | 2 |
| Grill, V | 2 |
| Martin, TJ | 3 |
| Davenport, A | 1 |
| Goel, S | 1 |
| Mackenzie, JC | 1 |
| Schilling, T | 2 |
| Blind, E | 2 |
| Zimmer-Roth, I | 1 |
| Baumgartner, G | 1 |
| Ziegler, R | 2 |
| Raue, F | 2 |
| Newrick, PG | 1 |
| Braatvedt, GD | 1 |
| Webb, AJ | 1 |
| Sheffield, E | 1 |
| Corrall, RJ | 1 |
| Ishimura, E | 1 |
| Miki, T | 1 |
| Koyama, H | 1 |
| Harada, K | 1 |
| Nakatsuka, K | 1 |
| Inaba, M | 1 |
| Nishizawa, Y | 1 |
| Morii, H | 1 |
| Brossard, JH | 1 |
| Garon, J | 1 |
| Lepage, R | 1 |
| Gascon-Barré, M | 1 |
| D'Amour, P | 1 |
| Lichinitser, MR | 1 |
| Vyshinskaia, GV | 1 |
| Kupchan, DZ | 1 |
| Liubimova, NV | 1 |
| Profumo, RJ | 1 |
| Reese, JC | 1 |
| Foy, TM | 1 |
| Garibaldi, LR | 1 |
| Kane, RE | 1 |
| Thirion, M | 1 |
| Cleeren, A | 3 |
| Nussbaum, SR | 1 |
| Younger, J | 1 |
| Vandepol, CJ | 1 |
| Gagel, RF | 1 |
| Zubler, MA | 1 |
| Henderson, IC | 1 |
| Mallette, LE | 2 |
| Grutters, JC | 1 |
| Hermus, AR | 1 |
| de Mulder, PH | 1 |
| Beex, LV | 2 |
| Leidig, G | 1 |
| Hall, TG | 1 |
| Schaiff, RA | 1 |
| Rosenmund, A | 1 |
| Kinirons, MT | 1 |
| Iguchi, H | 2 |
| Katakami, H | 1 |
| Ichinose, Y | 1 |
| Nishi, Y | 1 |
| Tanaka, S | 1 |
| Hara, N | 2 |
| Ohta, M | 1 |
| Haji, M | 1 |
| Nawata, H | 1 |
| Carbone, LD | 1 |
| Land, MA | 1 |
| Stentz, FB | 1 |
| Palmieri, GM | 1 |
| Selby, PL | 1 |
| Davies, M | 2 |
| Marks, JS | 1 |
| Mawer, EB | 1 |
| Lichtenstein, A | 1 |
| Porter, L | 2 |
| Dimopoulos, MA | 1 |
| Bordoni, R | 1 |
| George, S | 1 |
| Lipton, A | 6 |
| Keller, A | 2 |
| Ballester, O | 1 |
| Kovacs, MJ | 1 |
| Blacklock, HA | 1 |
| Bell, R | 2 |
| Simeone, J | 2 |
| Reitsma, DJ | 2 |
| Seaman, J | 3 |
| Nesković-Konstantinović, Z | 1 |
| Mitrović, L | 2 |
| Petrović, J | 1 |
| Stamatović, L | 1 |
| Ristović, Z | 1 |
| Ralston, SH | 13 |
| Tal, A | 2 |
| Graves, L | 1 |
| Powers, K | 1 |
| Gerrard, GE | 1 |
| Dodwell, DJ | 3 |
| Vail, A | 1 |
| Watters, J | 1 |
| Overend, MA | 1 |
| Machado, CE | 1 |
| Flombaum, CD | 1 |
| Harvey, HA | 1 |
| Stewart, GO | 1 |
| Stuckey, BG | 1 |
| Ward, LC | 1 |
| Prince, RL | 1 |
| Gutteridge, DH | 1 |
| Constable, IJ | 1 |
| Paterson, AH | 2 |
| Powles, TJ | 1 |
| McCloskey, E | 1 |
| Hanson, J | 1 |
| Ashley, S | 1 |
| McIntyre, E | 1 |
| Bruera, E | 1 |
| Illidge, TM | 1 |
| Hussey, M | 1 |
| Godden, CW | 1 |
| Hiraga, T | 1 |
| Takada, M | 1 |
| Nakajima, T | 1 |
| Ozawa, H | 1 |
| Possinger, K | 1 |
| Flath, B | 1 |
| Akrivakis, K | 1 |
| Hortobagyi, GN | 2 |
| Theriault, RL | 2 |
| Blayney, D | 1 |
| Sinoff, C | 1 |
| Wheeler, H | 1 |
| Simeone, JF | 1 |
| Kise, H | 1 |
| Kobayashi, K | 1 |
| Arima, K | 1 |
| Yanagawa, M | 1 |
| Tochigi, H | 1 |
| Kawamura, J | 1 |
| Hioki, T | 1 |
| Sugiura, Y | 1 |
| Ford, JF | 1 |
| Green, J | 1 |
| Vinholes, J | 1 |
| Guo, CY | 1 |
| Eastell, R | 1 |
| Piccart, M | 1 |
| Williams, CJ | 1 |
| Smith, RA | 1 |
| Ball, RJ | 1 |
| Wilkinson, H | 1 |
| MacConnachie, AM | 1 |
| Malnick, SD | 1 |
| Ariel-Ronen, S | 1 |
| Evron, E | 1 |
| Sthoeger, ZM | 1 |
| Reading, PJ | 1 |
| Newman, PK | 1 |
| Kelly, WF | 1 |
| Bateson, MC | 1 |
| Rothwell, P | 1 |
| Sinha, RN | 1 |
| Fraser, WD | 5 |
| Casson, IF | 1 |
| Kutluk, MT | 1 |
| Hazar, V | 1 |
| Akyüz, C | 3 |
| Varan, A | 2 |
| Büyükpamukçu, M | 2 |
| Sakoulas, G | 1 |
| Tritos, NA | 1 |
| Lally, M | 1 |
| Wanke, C | 1 |
| Hartzband, P | 1 |
| Nakanishi, Y | 1 |
| Takayama, K | 1 |
| Young, G | 1 |
| Shende, A | 1 |
| Kedlaya, D | 1 |
| Brandstater, ME | 1 |
| Lee, JK | 1 |
| Coukell, AJ | 1 |
| Markham, A | 1 |
| Greenwald, RA | 1 |
| Stein, B | 1 |
| Miller, F | 1 |
| Kutluk, T | 2 |
| Yalçin, B | 2 |
| Büyükpamuküçu, M | 1 |
| Brincker, H | 1 |
| Westin, J | 1 |
| Abildgaard, N | 1 |
| Gimsing, P | 1 |
| Turesson, I | 1 |
| Hedenus, M | 1 |
| Ford, J | 1 |
| Kandra, A | 1 |
| Westphal, SA | 1 |
| Endo, K | 1 |
| Katsumata, K | 1 |
| Kubodera, N | 1 |
| Teramoto, T | 1 |
| Ikeda, K | 1 |
| Fujita, T | 1 |
| Ogata, E | 1 |
| Lteif, AN | 1 |
| Zimmerman, D | 1 |
| Ylitalo, R | 1 |
| Kalliovalkama, J | 1 |
| Wu, X | 1 |
| Kankaanranta, H | 1 |
| Salenius, JP | 1 |
| Sisto, T | 1 |
| Lähteenmäki, T | 1 |
| Ylitalo, P | 1 |
| Pörsti, I | 1 |
| Kakizaki, S | 1 |
| Ohya, N | 1 |
| Yoshinaga, T | 1 |
| Higuchi, T | 1 |
| Kitazawa, R | 1 |
| Takayama, H | 1 |
| Takagi, H | 1 |
| Nagamine, T | 1 |
| Mori, M | 1 |
| Loh, K | 1 |
| Matthay, KK | 1 |
| Hoover, M | 1 |
| Bracho, FA | 1 |
| Cortez, AB | 1 |
| Conte, FA | 1 |
| Albanese, CT | 1 |
| Miller, TR | 1 |
| Price, DC | 1 |
| Flores, AJ | 1 |
| Kaviani, A | 1 |
| Shoback, D | 1 |
| Bartl, R | 1 |
| Diel, IJ | 2 |
| Fleisch, H | 2 |
| Kyle, RA | 1 |
| Rubens, RD | 2 |
| Lee, DC | 1 |
| Lee, GY | 1 |
| Sellers, E | 1 |
| Sharma, A | 1 |
| Rodd, C | 1 |
| Sims, EC | 1 |
| Rogers, PB | 1 |
| Besser, GM | 1 |
| Plowman, PN | 1 |
| Leff, R | 1 |
| Glück, S | 1 |
| Stewart, JF | 1 |
| Costello, S | 1 |
| Kennedy, I | 1 |
| Seaman, JJ | 1 |
| Mellars, K | 1 |
| Attard, TM | 1 |
| Dhawan, A | 1 |
| Kaufman, SS | 1 |
| Collier, DS | 1 |
| Langnas, AN | 1 |
| Hotta, M | 1 |
| Shibasaki, T | 1 |
| Cila, A | 1 |
| Koshida, H | 1 |
| Kametani, T | 1 |
| Masuda, S | 1 |
| De Schepper, J | 1 |
| de Pont, S | 1 |
| Smitz, J | 1 |
| De Coster, D | 1 |
| Schots, R | 1 |
| Otten, J | 1 |
| Massagli, TL | 1 |
| Cardenas, DD | 1 |
| Rumbeiha, WK | 1 |
| Kruger, JM | 1 |
| Fitzgerald, SF | 1 |
| Nachreiner, RF | 1 |
| Kaneene, JB | 1 |
| Braselton, WE | 1 |
| Chiapuzio, CL | 1 |
| Lortholary, A | 4 |
| Jadaud, E | 1 |
| Berthaud, P | 1 |
| Tezer Kutluk, M | 1 |
| Kusama, M | 1 |
| Kaise, H | 1 |
| Nakayama, S | 1 |
| Ota, D | 1 |
| Aoki, T | 1 |
| Koyanagi, Y | 1 |
| Matsunaga, T | 1 |
| Nakamura, Y | 1 |
| McCloskey, EV | 1 |
| Felsenfeld, AJ | 1 |
| Jara, A | 1 |
| Avedian, G | 1 |
| Kleeman, CR | 1 |
| Louviaux, I | 1 |
| Riehl, J | 1 |
| Brandenburg, VM | 1 |
| Dietrich, CG | 1 |
| Block, F | 1 |
| Akbulut, H | 1 |
| Icli, F | 1 |
| Rasmuson, T | 1 |
| Kristoffersson, A | 1 |
| Boquist, L | 1 |
| Hon, J | 1 |
| Abdi, E | 1 |
| Mills, G | 1 |
| Menssen, HD | 1 |
| Yunus, F | 1 |
| Body, J | 1 |
| Quebe-Fehling, E | 1 |
| Nikolic-Tomasević, Z | 1 |
| Jelic, S | 1 |
| Popov, I | 1 |
| Radosavljević, D | 1 |
| Khan, N | 1 |
| Licata, A | 1 |
| Rogers, D | 1 |
| Iwase, M | 1 |
| Kurachi, Y | 1 |
| Kakuta, S | 1 |
| Sakamaki, H | 1 |
| Nakamura-Mitsuhashi, M | 1 |
| Nagumo, M | 1 |
| Shanks, D | 1 |
| Linke, R | 1 |
| Saxon, B | 1 |
| Solomayer, EF | 1 |
| Bastert, G | 1 |
| Ostenstad, B | 1 |
| Andersen, OK | 1 |
| Okada, M | 1 |
| Noguchi, S | 1 |
| Hasegawa, Y | 1 |
| Inukai, T | 1 |
| Gallacher, SJ | 8 |
| Logue, FC | 4 |
| Dryburgh, FJ | 6 |
| Cowan, RA | 5 |
| Boyle, IT | 15 |
| Kellihan, MJ | 1 |
| Mangino, PD | 1 |
| Weatherall, M | 1 |
| Morton, AR | 4 |
| Daley-Yates, PT | 1 |
| Hoggarth, CR | 1 |
| Waldburger, R | 1 |
| Senn, HJ | 1 |
| Christensen, JH | 1 |
| Kristiansen, JH | 1 |
| Seraj, F | 2 |
| Murray, RM | 2 |
| Ho, PW | 1 |
| Santamaria, JD | 1 |
| Pitt, P | 1 |
| Potts, C | 1 |
| Jerums, G | 1 |
| Fitton, A | 1 |
| McTavish, D | 1 |
| Ritch, P | 1 |
| Wiernik, PH | 1 |
| Sarma, PR | 1 |
| Richman, SP | 1 |
| Tauer, K | 1 |
| Neidhart, J | 1 |
| Siegel, R | 1 |
| Abbas, SK | 1 |
| Varache, N | 1 |
| Audran, M | 1 |
| Clochon, P | 1 |
| Bouachour, G | 1 |
| Alquier, P | 1 |
| Basle, MF | 1 |
| Janisch, S | 1 |
| Marosi, C | 1 |
| Wogritsch, C | 1 |
| Bosse, C | 1 |
| Schratzberger, W | 1 |
| Gerber, E | 1 |
| Fortelny, A | 1 |
| Lenzhofer, R | 1 |
| Rainer, H | 1 |
| Vega, EM | 1 |
| Mautalen, CA | 1 |
| Campbell, JH | 1 |
| Ralston, S | 1 |
| Banham, SW | 1 |
| Tisell, LE | 2 |
| Lindstedt, G | 2 |
| Lundberg, PA | 2 |
| Hurtado, J | 1 |
| Esbrit, P | 1 |
| Rapado, A | 1 |
| O'Reilly, DS | 1 |
| Beastall, GH | 1 |
| Kwan, JT | 1 |
| Cunningham, J | 3 |
| Patel, U | 2 |
| Judson, I | 1 |
| Booth, F | 1 |
| Gore, M | 1 |
| McElwain, T | 1 |
| Friefeld, J | 1 |
| Halperin, F | 1 |
| Rawlinson, PS | 1 |
| Green, RH | 1 |
| Coggins, AM | 1 |
| Gibson, BE | 1 |
| Hoekman, K | 1 |
| Tjandra, YI | 1 |
| Papapoulos, SE | 2 |
| Wisneski, LA | 1 |
| Campbell, J | 1 |
| Warrell, RP | 3 |
| Raymakers, JA | 2 |
| Cantwell, BM | 3 |
| Wingren, U | 1 |
| Jacquet, AF | 5 |
| Boudailliez, BR | 1 |
| Pautard, BJ | 1 |
| Sebert, JL | 1 |
| Kremp, O | 1 |
| Piussan, CX | 1 |
| Devogelaer, JP | 1 |
| Lambert, M | 1 |
| Boland, B | 1 |
| Godfraind, C | 1 |
| Noel, H | 1 |
| Nagant de Deuxchaisnes, C | 1 |
| Allam, BF | 1 |
| Boyce, BF | 1 |
| Yap, AS | 1 |
| Hockings, GI | 1 |
| Fleming, SJ | 1 |
| Khafagi, FA | 1 |
| Hené, RJ | 1 |
| Visser, WJ | 1 |
| Duursma, SA | 1 |
| de bos Kuil, RJ | 1 |
| Dorhout Mees, EJ | 1 |
| Jaeger, P | 5 |
| Sawyer, N | 2 |
| Newstead, C | 2 |
| Drummond, A | 2 |
| Canivet, JL | 1 |
| Damas, P | 1 |
| Lamy, M | 1 |
| Kefford, R | 1 |
| Stuart-Harris, R | 1 |
| Newland, A | 1 |
| McIntyre, HD | 1 |
| Cameron, DP | 1 |
| Urquhart, SM | 1 |
| Davies, WE | 1 |
| Magritte, A | 1 |
| Sculier, JP | 2 |
| Borkowski, A | 4 |
| Perey, L | 1 |
| von Fliedner, V | 1 |
| Mannix, KA | 1 |
| Carmichael, J | 1 |
| Harris, AL | 3 |
| Davis, JR | 1 |
| Gardner, MD | 5 |
| Jenkins, AS | 2 |
| Cantwell, B | 1 |
| Jodrell, DI | 1 |
| Iveson, TJ | 1 |
| Smith, IE | 1 |
| van Holten-Verzantvoort, AT | 1 |
| Cleton, FJ | 1 |
| Hermans, J | 1 |
| Kroon, HM | 1 |
| Harinck, HI | 3 |
| Vermey, P | 1 |
| Elte, JW | 2 |
| Neijt, JP | 2 |
| McKillop, JH | 1 |
| Alzaid, AA | 3 |
| Cantrill, JA | 1 |
| Craig, AE | 1 |
| Anderson, DC | 1 |
| Tan, TT | 1 |
| Sutcliffe, N | 1 |
| Thomson, JA | 1 |
| Heaf, JG | 1 |
| Hansen, M | 1 |
| Rischin, D | 1 |
| Bishop, JF | 1 |
| Plantingh, AS | 1 |
| Wildiers, J | 1 |
| Glibert, F | 1 |
| Nejai, S | 1 |
| Yates, AJ | 1 |
| Jerums, GJ | 1 |
| Evans, RA | 1 |
| Fraher, LJ | 1 |
| Pot, M | 1 |
| Klastersky, J | 1 |
| Portmann, L | 1 |
| Gibbs, CJ | 1 |
| Peacock, M | 1 |
| Fuss, M | 1 |
| Karmali, R | 1 |
| Gillet, C | 1 |
| Corvilain, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Bone Biopsy for Histomorphometry and Analysis of Bone Marrow Derived Osteoblast and Osteoclast Progenitors to Explore Mechanisms of Decreased Bone Mineral Density in Depression[NCT00001916] | 17 participants | Observational | 1999-03-31 | Completed | |||
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631] | Phase 2 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
45 reviews available for pamidronate and Milk-Alkali Syndrome
| Article | Year |
|---|---|
Hypercalcemia: A Review.
Topics: Calcium; Coma; COVID-19; Dehydration; Denosumab; Humans; Hypercalcemia; Hyperparathyroidism, Primary | 2022 |
Refractory Hypercalcemia in Squamous Cell Carcinoma of the Esophagus-a Case Report and Review of Literature.
Topics: Calcitonin; Calcium; Calcium-Regulating Hormones and Agents; Carcinoma, Squamous Cell; Cinacalcet; D | 2019 |
Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review.
Topics: Acute Disease; Bone and Bones; Bone Resorption; Female; Humans; Hypercalcemia; Middle Aged; Pamidron | 2019 |
Importance of dietary calcium and vitamin D in the treatment of hypercalcaemia in Williams-Beuren syndrome.
Topics: Calcitriol; Calcium, Dietary; Child, Preschool; Diphosphonates; Female; Gene Deletion; Humans; Hyper | 2014 |
Hypercalcemia in pediatric acute megakaryocytic leukemia: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases, Met | 2009 |
Supportive therapy in multiple myeloma.
Topics: Anemia; Blood Transfusion; Bone Diseases; Calcitonin; Clodronic Acid; Diphosphonates; Erythropoietin | 2011 |
Modern management of malignant hypercalcemia.
Topics: Bone Density Conservation Agents; Calcitonin; Clinical Protocols; Diphosphonates; Fluid Therapy; Gal | 2011 |
The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Topics: Anti-Inflammatory Agents; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Humans; | 2002 |
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; | 2002 |
Treatment of hypercalcemia of malignancy with bisphosphonates.
Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; H | 2002 |
Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity.
Topics: Aged; Creatinine; Diphosphonates; Humans; Hypercalcemia; Kidney; Kidney Tubular Necrosis, Acute; Mal | 2003 |
Hypercalcemia of malignancy.
Topics: Antineoplastic Agents; Diphosphonates; Forecasting; Humans; Hypercalcemia; Imidazoles; Neoplasms; Pa | 2004 |
Safety and convenience of a 15-minute infusion of zoledronic acid.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandr | 2004 |
[Treatment of Paget's disease of bone: importance of the zoledronic acid].
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Dipho | 2006 |
Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects?
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Hypercal | 1994 |
Update on the medical treatment of hypercalcemia of malignancy.
Topics: Animals; Antineoplastic Agents; Calcitonin; Diphosphonates; Etidronic Acid; Gallium; Humans; Hyperca | 1993 |
[Hypercalcemia as an emergency].
Topics: Calcitonin; Calcium; Diphosphonates; Emergencies; Fluid Therapy; Furosemide; Humans; Hypercalcemia; | 1993 |
Newer agents for the treatment of malignant hypercalcemia.
Topics: Diphosphonates; Etidronic Acid; Gallium; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1993 |
Pathogenesis and management of cancer associated hypercalcaemia.
Topics: Antineoplastic Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Diuretics; Etidronic Aci | 1994 |
Bone and cancer: pathophysiology and treatment of metastases.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Diseases, Metabolic; Bone Neoplasms; Breast Neoplasms | 1995 |
[Bisphosphonates in the treatment concept of metastatic breast carcinoma].
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemi | 1996 |
Use of bisphosphonates in cancer patients.
Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid | 1996 |
Pamidronate (Aredia, Ciba) in malignant hypercalcaemia.
Topics: Diphosphonates; Drug Monitoring; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1997 |
Rationale for the use of bisphosphonates in breast cancer.
Topics: Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Clodronic Acid; Cost-Benefit Analysis; Diphosphon | 1996 |
[Paraneoplastic syndrome].
Topics: Alendronate; Anticoagulants; Cushing Syndrome; Diagnosis, Differential; Diphosphonates; Disseminated | 1997 |
Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypercalcemia; Neopl | 1998 |
Bisphosphonates for treatment of childhood hypercalcemia.
Topics: Adolescent; Calcium; Child, Preschool; Diphosphonates; Female; Humans; Hypercalcemia; Immobilization | 1998 |
Undifferentiated pancreatic cancer associated with humoral hypercalcemia of malignancy.
Topics: Antineoplastic Agents; Carcinoma; Diphosphonates; Humans; Hypercalcemia; Liver Neoplasms; Male; Midd | 1998 |
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodron | 1998 |
The role of bisphosphonates for the treatment of bone disease in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Bone Remodeling; Clinical Trials as Topic; Clodronic Acid; Diphospho | 1998 |
[Bisphosphonates and bone metastases].
Topics: Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonat | 1999 |
Bisphosphonates in multiple myeloma.
Topics: Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Multiple Myeloma; Pain; Pamid | 2000 |
Current and future directions in medical therapy: hypercalcemia.
Topics: Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamid | 2000 |
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
Topics: Adult; Aged; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Neoplasms | 2001 |
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
Topics: Diagnosis, Differential; Diagnostic Errors; Diphosphonates; Etidronic Acid; Fluid Therapy; Hematolog | 2001 |
Treatment of metastatic bone disease in breast cancer: bisphosphonates.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D | 2000 |
Pamidronate.
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Osteitis Deformans; | 1992 |
Bone metastases and tumor-induced hypercalcemia.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Calcitonin; Combined Modality Therapy; Dipho | 1992 |
Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Topics: Animals; Bone Resorption; Diphosphonates; Drug Evaluation; Humans; Hypercalcemia; Osteitis Deformans | 1991 |
Salmon calcitonin in the acute management of hypercalcemia.
Topics: Adrenal Cortex Hormones; Calcitonin; Calcium; Diphosphonates; Gallium; Humans; Hypercalcemia; Pamidr | 1990 |
Hypercalcemia and bone metastases in breast cancer.
Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper | 1990 |
[Hypercalcemia in the elderly].
Topics: Aged; Calcitonin; Calcium; Combined Modality Therapy; Diphosphonates; Female; Fluid Therapy; Homeost | 1990 |
Disodium pamidronate, bisphosphonate for malignant hypercalcaemia.
Topics: Diphosphonates; Drug Administration Schedule; Female; Humans; Hypercalcemia; Pamidronate | 1990 |
1,25-Dihydroxyvitamin D-related hypercalcemia in lymphoma: two case reports.
Topics: Aged; Calcitriol; Cataract; Diphosphonates; Female; Glucocorticoids; Humans; Hypercalcemia; Lymphoma | 1990 |
[Biphosphonate as a therapeutic drug--experimental studies and clinical application].
Topics: Animals; Calcinosis; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Hyperpar | 1985 |
41 trials available for pamidronate and Milk-Alkali Syndrome
| Article | Year |
|---|---|
Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis.
Topics: Aged; Bone Density; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; K | 2003 |
Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Bone Resorption; Diphosphonates; Female; Human | 2003 |
Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia.
Topics: Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Female; Humans; Hypercalcemia; Infusio | 2003 |
Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia.
Topics: Adult; Aged; Calcium; Diphosphonates; Female; Fluid Therapy; Follow-Up Studies; Glomerular Filtratio | 1983 |
Comparative study of available medical therapy for hypercalcemia of malignancy.
Topics: Administration, Oral; Adult; Aged; Calcium; Clinical Trials as Topic; Diphosphonates; Etidronic Acid | 1983 |
A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Topics: Bone Neoplasms; Bone Resorption; Clodronic Acid; Diphosphonates; Double-Blind Method; Humans; Hyperc | 1995 |
Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy.
Topics: Diphosphonates; Drug Administration Schedule; Female; Humans; Hypercalcemia; Pamidronate; Time Facto | 1994 |
Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
Topics: Bone Neoplasms; Calcium; Diphosphonates; Humans; Hypercalcemia; Infusions, Intravenous; Kidney Tubul | 1994 |
Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
Topics: Adult; Breast Neoplasms; Calcium; Diphosphonates; Double-Blind Method; Drug Administration Schedule; | 1994 |
Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Male; Middle | 1994 |
Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Topics: Aged; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperca | 1993 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Drug Monitoring; Female; Hum | 1995 |
The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; | 1996 |
[Bisphosphonates in the treatment concept of metastatic breast carcinoma].
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemi | 1996 |
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Disease-Fr | 1996 |
Pamidronate in the treatment of osteolytic bone metastases in breast cancer patients.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Pa | 1996 |
Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Topics: Adult; Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Neoplasms; Bone Resorption; Calcium; C | 1997 |
Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols | 1998 |
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Disea | 1999 |
Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
Topics: Adult; Aged; Anti-Inflammatory Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcem | 2000 |
Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia.
Topics: Diphosphonates; Humans; Hypercalcemia; Neoplasms; Pamidronate; Plicamycin | 1992 |
Pamidronate.
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Osteitis Deformans; | 1992 |
Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Drug Administration Schedule; Female; Humans; Hyperc | 1992 |
Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Hypercalcemia; Male; Middle Aged; Ne | 1992 |
Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
Topics: Adult; Aged; Analysis of Variance; Calcium; Diphosphonates; Double-Blind Method; Etidronic Acid; Fem | 1992 |
[Pamidronate in the treatment of tumor-associated hypercalcemia].
Topics: Adult; Aged; Calcium; Diphosphonates; Female; Fluid Therapy; Humans; Hypercalcemia; Male; Middle Age | 1991 |
Hypercalcemia and bone metastases in breast cancer.
Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper | 1990 |
[A new osteoclast inhibitor is useful in the treatment of severe hypercalcemia].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Diphosphonates; Female; Humans; Hypercalcemia; Ma | 1990 |
Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia.
Topics: Calcium; Creatinine; Diphosphonates; Humans; Hypercalcemia; Kinetics; Neoplasms; Pamidronate | 1990 |
Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.
Topics: Adult; Aged; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Hematologic Test | 1989 |
Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Infusions, I | 1989 |
Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
Topics: Calcitonin; Calcium; Clinical Trials as Topic; Creatinine; Diphosphonates; Drug Therapy, Combination | 1985 |
Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosph | 1987 |
Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer.
Topics: Adult; Aged; Diphosphonates; Female; Humans; Hypercalcemia; Male; Middle Aged; Neoplasms; Pamidronat | 1987 |
Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
Topics: Calcium; Diphosphonates; Drug Administration Schedule; Female; Humans; Hypercalcemia; Infusions, Int | 1988 |
Treatment of hypercalcaemia of malignancy.
Topics: Diphosphonates; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1988 |
Questions about clinical trials in hypercalcemia.
Topics: Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1988 |
Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride.
Topics: Adult; Aged; Aged, 80 and over; Bone Resorption; Calcium; Clinical Trials as Topic; Diphosphonates; | 1987 |
[Treatment of neoplastic hypercalcemia using single-infusion diphosphonate].
Topics: Adult; Aged; Bone Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Female; Huma | 1988 |
228 other studies available for pamidronate and Milk-Alkali Syndrome
| Article | Year |
|---|---|
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques | 2002 |
Isolated splenic sarcoidosis: a rare cause of hypercalcaemia in a patient with type 1 diabetes.
Topics: Adult; Diabetes Mellitus, Type 1; Humans; Hypercalcemia; Male; Pamidronate; Sarcoidosis; Splenic Dis | 2021 |
Severe neonatal hypercalcemia revealing congenital mesoblastic nephroma: A case report and management of neonatal hypercalcemia: Severe neonatal hypercalcemia revealing congenital mesoblastic nephroma.
Topics: Calcium; Female; Food, Fortified; Furosemide; Humans; Hypercalcemia; Hypertension; Infant Formula; I | 2022 |
Pamidronate versus zoledronic acid for the treatment of multiple myeloma-related hypercalcemia.
Topics: Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2022 |
Use of Pamidronate for Hypercalcemia of Malignancy in Renal Dysfunction.
Topics: Acute Kidney Injury; Diphosphonates; Humans; Hypercalcemia; Indiana; Neoplasms; Pamidronate; Retrosp | 2021 |
Severe hypercalcaemia due to household cleaner ingestion.
Topics: Acute Kidney Injury; Anti-Inflammatory Agents; Bone Density Conservation Agents; Eating; Household P | 2019 |
Efficacy and Safety of Intravenous Pamidronate for Parathyroid Hormone-dependent Hypercalcemia in Hospitalized Patients.
Topics: Administration, Intravenous; Aged; Bone Density Conservation Agents; Calcium; Case-Control Studies; | 2021 |
Treatment of extreme hypercalcaemia: the role of haemodialysis.
Topics: Adenoma; Aged; Bone Density Conservation Agents; Calcitonin; Dexamethasone; Diphosphonates; Fluid Th | 2018 |
Risks of the 'Sunshine pill' - a case of hypervitaminosis D.
Topics: Aged; Bone Density Conservation Agents; Humans; Hypercalcemia; Male; Nutrition Disorders; Pamidronat | 2018 |
Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Female; Humans; Hypercalcemia; K | 2018 |
Acute renal failure due to severe hypercalcemia and nephrocalcinosis treated with two doses of pamidronate in an infant with Williams-Beuren syndrome.
Topics: Acute Kidney Injury; Bone Density Conservation Agents; Female; Humans; Hypercalcemia; In Situ Hybrid | 2018 |
Comparison of Treatment Regimens in Management of Severe Hypercalcemia Due to Vitamin D Intoxication in Children
Topics: Bone Density Conservation Agents; Female; Follow-Up Studies; Humans; Hypercalcemia; Infant; Male; Pa | 2019 |
A case of severe, irreversible hypocalcemia after one dose of pamidronate administered for hypercalcemia of malignancy.
Topics: Bone Neoplasms; Calcium; Humans; Hypercalcemia; Hypocalcemia; Male; Middle Aged; Pamidronate; Risk F | 2019 |
Primary isolated hepatosplenic sarcoidosis mimicking malignancy and causing symptomatic hypercalcaemia.
Topics: Aftercare; Aged; Bone Density Conservation Agents; Diagnosis, Differential; Female; Humans; Hypercal | 2019 |
Visual Diagnosis: An Infant with Rash and Hypercalcemia.
Topics: Exanthema; Fat Necrosis; Humans; Hypercalcemia; Hypothermia, Induced; Infant, Newborn; Male; Pamidro | 2019 |
Bisphosphonates for treatment of severe idiopathic infantile hypercalcemia.
Topics: Bone Density Conservation Agents; Calcium; Diphosphonates; Humans; Hypercalcemia; Male; Pamidronate; | 2013 |
Intravenous pamidronate in the treatment of severe idiopathic infantile hypercalcemia.
Topics: Biomarkers; Bone Density Conservation Agents; Calcium; Child, Preschool; Diagnosis, Differential; Di | 2013 |
Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy.
Topics: Aged; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Carcinoma, Squamous C | 2014 |
Prolonged hypocalcaemia after pamidronate infusion in Riedel's thyroiditis associated hypoparathyroidism.
Topics: Bone Density Conservation Agents; Calcium Carbonate; Dihydrotachysterol; Diphosphonates; Female; Gas | 2013 |
An infant with hypercalcemia: questions.
Topics: Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Humans; Hypercalcemia; In | 2014 |
Exceptional localisation of an ectopic parathyroid adenoma at the level of the hyoid bone.
Topics: Adenoma; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Hyoid Bone; Hypercalcemia | 2014 |
Renal replacement therapy as a treatment for severe refractory hypercalcemia.
Topics: Adenoma; Adult; Carcinoma; Cinacalcet; Diphosphonates; Drug Resistance; Emergencies; Female; Furosem | 2014 |
Pamidronate for long-term control of hypercalcemia associated with Williams syndrome.
Topics: Child, Preschool; Diphosphonates; Humans; Hypercalcemia; Male; Pamidronate; Williams Syndrome | 2015 |
Quality and Outcomes of Treatment of Hypercalcemia of Malignancy.
Topics: Aged; Bone Neoplasms; Calcitonin; Diphosphonates; Diuretics; Female; Glucocorticoids; Humans; Hyperc | 2015 |
Case 4: How Much Is Too Much? A Case of Hypercalcemia in a 6-year-old Boy.
Topics: Bone Density Conservation Agents; Calcitonin; Child; Diagnosis, Differential; Dietary Supplements; D | 2015 |
Just hypercalcaemia or acute ST elevation myocardial infarction? A review of hypercalcaemia-related electrocardiographic changes.
Topics: Aged; Bone Density Conservation Agents; Calcitonin; Calcium; Diphosphonates; Disease Management; Ele | 2015 |
Severe hypercalcaemia in a child secondary to use of alternative therapies.
Topics: Autistic Disorder; Bone Density Conservation Agents; Calcium; Child, Preschool; Complementary Therap | 2016 |
Effectiveness of pamidronate in severe neonatal hypercalcemia caused by subcutaneous fat necrosis: a case report.
Topics: Anti-Inflammatory Agents; Child; Child, Preschool; Diphosphonates; Fat Necrosis; Female; Humans; Hyp | 2009 |
Commentary on 'Pamidronate: treatment for severe hypercalcemia in neonatal subcutaneous fat necrosis' by Alos N. et al., Hormone Research 2006;65:289-294.
Topics: Bone Density Conservation Agents; Calcium; Diphosphonates; Fat Necrosis; Female; Humans; Hypercalcem | 2008 |
Reversal of hypercalcemic acute kidney injury by treatment with intravenous bisphosphonates.
Topics: Acute Disease; Adolescent; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates | 2009 |
Hypercalcemia and overexpression of CYP27B1 in a patient with nephrogenic systemic fibrosis: clinical vignette and literature review.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Aged; Diphosphonates; Humans; Hypercalcemia; Leukemia, Lym | 2009 |
Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient.
Topics: Aged; Calcium; Diphosphonates; Humans; Hypercalcemia; Hyperparathyroidism; Kidney Failure, Chronic; | 2009 |
Hypercalcemia of immobilization.
Topics: Bone Density Conservation Agents; Diphosphonates; Diuretics; Fluid Therapy; Furosemide; Humans; Hype | 2009 |
A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
Topics: Aged; Algorithms; Bone Density Conservation Agents; Calcitonin; Carcinoma, Transitional Cell; Crysta | 2009 |
[Paget's disease and hypercalcemia: coincidence or causal relationship?].
Topics: Aged; Anti-Inflammatory Agents; Diphosphonates; Female; Fractures, Bone; Humans; Hypercalcemia; Oste | 2009 |
[Efficient treatment of hypercalcaemia in neonatal subcutaneous fat necrosis].
Topics: Asphyxia Neonatorum; Diphosphonates; Fat Necrosis; Female; Humans; Hypercalcemia; Infant, Newborn; I | 2010 |
Nephrotic syndrome induced by pamidronate.
Topics: Adenocarcinoma; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Huma | 2011 |
Use of bisphosphonates to treat severe idiopathic hypercalcaemia in a young Ragdoll cat.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Cat Diseases; Cats; Diphosphonates; Female; | 2011 |
Severe hypercalcemia associated with uterine leiomyoma in pregnancy.
Topics: Adult; Calcitriol; Calcium; Critical Care; Diphosphonates; Female; Gynecologic Surgical Procedures; | 2011 |
Severe hypercalcemia associated with Williams syndrome successfully treated with pamidronate infusion therapy.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Hypercalcemia; Infant; Infusion Pu | 2011 |
Hyperparathyroidism due to eutopic PTH secretion from an ectopic intrathymic parathyroid cyst.
Topics: Biomarkers; Biopsy; Calcitonin; Calcium; Choristoma; Diphosphonates; Diuretics; Female; Fluid Therap | 2011 |
A case of myeloma with hypercalcemia caused by high serum concentrations of both parathyroid hormone-related peptide (PTHrP) and macrophage inflammatory protein-1α (MIP-1α).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Calcitonin; Calciu | 2011 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conserv | 2012 |
Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bre | 2013 |
Megakaryoblastic transformation of polycythemia vera with hypercalcemia.
Topics: Adrenocorticotropic Hormone; Bone Resorption; Busulfan; Calcium; Cell Transformation, Neoplastic; Di | 2002 |
[Treatment of hypercalcemia of malignancy with pamidronate in a patient with advanced recurrent oral cancer].
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Consciousness Disorders; Diphosphonates; Dru | 2002 |
Immobilization hypercalcemia in critical illness following bariatric surgery.
Topics: Adult; Diphosphonates; Gastroplasty; Humans; Hypercalcemia; Immobilization; Male; Pamidronate; Parat | 2002 |
Hypercalcemia due to sun exposure in a patient with multiple myeloma and elevated parathyroid hormone-related protein.
Topics: Adult; Alkaline Phosphatase; Anti-Inflammatory Agents, Non-Steroidal; Diphosphonates; Humans; Hyperc | 2003 |
Treatment of acute lymphoblastic leukemia-induced extreme hypercalcemia with pamidronate and calcitonin.
Topics: Antineoplastic Agents; Calcitonin; Child; Diphosphonates; Female; Humans; Hypercalcemia; Pamidronate | 2003 |
Pamidronate in a girl with chronic renal insufficiency dependent on parenteral nutrition.
Topics: Anti-Inflammatory Agents; Calcitonin; Child; Chlorothiazide; Colonic Diseases; Diphosphonates; Diure | 2003 |
The use of subcutaneous pamidronate.
Topics: Anti-Inflammatory Agents; Diphosphonates; Humans; Hypercalcemia; Injections, Subcutaneous; Pamidrona | 2003 |
Isolated adrenocorticotropic hormone deficiency presenting with hypercalcemia in a patient on long-term hemodialysis.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Adult; Calcitriol; Corticotropin-Releasing Hormo | 2003 |
Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Topics: Aged; Chronic Kidney Disease-Mineral and Bone Disorder; Diphosphonates; Female; Humans; Hypercalcemi | 2003 |
Vitamin D intoxication and hypercalcaemia in an infant treated with pamidronate infusions.
Topics: Anti-Inflammatory Agents; Diphosphonates; Humans; Hypercalcemia; Infant; Infusions, Intravenous; Mal | 2004 |
Hypercalcemia in patients with disseminated coccidioidomycosis.
Topics: Adult; Aged; Calcium; Coccidioidomycosis; Diphosphonates; Etidronic Acid; Female; Humans; Hypercalce | 2004 |
A single bisphosphonate infusion is associated with improved functional capacity in elderly subjects with primary hyperparathyroidism.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antimetabolites; Bone and Bones; Bone Resorptio | 2003 |
Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.
Topics: Bone Resorption; Breast Neoplasms; Diphosphonates; Drug Resistance; Female; Humans; Hypercalcemia; I | 2004 |
Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy.
Topics: Antineoplastic Agents; Dehydration; Diphosphonates; DNA Mutational Analysis; Female; Genotype; Human | 2004 |
Pamidronate treatment for hypercalcemia in an infant receiving parenteral nutrition.
Topics: Diphosphonates; Humans; Hypercalcemia; Infant, Newborn; Male; Pamidronate; Parenteral Nutrition | 2004 |
Long-term control of hypercalcaemia in an infant with williams-Beuren syndrome after a single infusion of biphosphonate (Pamidronate).
Topics: Anti-Inflammatory Agents; Calcium; Diphosphonates; Follow-Up Studies; Humans; Hypercalcemia; Infant; | 2004 |
[Treatment of multiple myeloma with intravenous pamidronate. Pain prevention and suppression of hypercalcemia risk].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Diphosphonates; Female; Humans; Hypercalcemia; Injec | 2004 |
Severe infantile hypercalcemia associated with Williams syndrome successfully treated with intravenously administered pamidronate.
Topics: Calcium, Dietary; Diphosphonates; Female; Humans; Hypercalcemia; Infant; Infusions, Intravenous; Mal | 2004 |
Biochemical effects from treatment with bisphosphonate and surgery in patients with primary hyperparathyroidism.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Diphosphonates; Female; Homeostasis; Human | 2004 |
Hypercalcemia and childhood cancer: a 7-year experience.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Diphosphonates; Female; Humans; Hypercal | 2005 |
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Carrier Proteins; Cell Lin | 2005 |
The issue of renal safety of zoledronic acid from a nephrologist's point of view.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandr | 2005 |
"Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandr | 2005 |
[Hypercalcemia and childhood cancer].
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Diphosphonates; Female; Humans; Hypercal | 2005 |
Ionized calcium in isolation may not detect all cases of symptomatic hypercalcaemia.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Calcium; Diphosphonates; Female; Humans; Hyperca | 2005 |
Chronic hypercalcemia as a reversible cause of cognitive impairment: improvement after a single administration of pamidronate.
Topics: Aged; Chronic Disease; Cognition Disorders; Diphosphonates; Female; Humans; Hypercalcemia; Hyperpara | 2005 |
The use of pamidronate in a leukemic child with immobilization hypercalcemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphos | 2006 |
Osteonecrosis of the jaws and bisphosphonates. Report of three cases.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalce | 2006 |
[Reversible posterior leucoencephalopathy due to hypercalcaemia].
Topics: Antineoplastic Agents; Blindness, Cortical; Brain Diseases; Cognition Disorders; Diagnosis, Differen | 2006 |
Pamidronate: Treatment for severe hypercalcemia in neonatal subcutaneous fat necrosis.
Topics: Bone Density Conservation Agents; Calcium; Diphosphonates; Fat Necrosis; Female; Humans; Hypercalcem | 2006 |
An unrecognized cause of recurrent hypercalcemia: immobilization.
Topics: Aged; Bone Density Conservation Agents; Calcium; Diphosphonates; Exercise Therapy; Gout; Humans; Hyp | 2006 |
Bisphosphonate-associated arthritis.
Topics: Arthritis; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Fatal Outcome; Female | 2006 |
[The incidence and management of bone metastasis from breast cancer].
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; | 2006 |
Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient.
Topics: Antineoplastic Agents; Diphosphonates; Humans; Hypercalcemia; Kidney Failure, Chronic; Male; Middle | 2006 |
Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Breech Presentation; Cesarean Sectio | 2006 |
Hypercalcaemia in a patient with a gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, C | 2007 |
[Hypercalcaemia and malignant lymphoma. One case report].
Topics: Aged, 80 and over; Bone Density Conservation Agents; Calcitriol; Diphosphonates; Glucocorticoids; Hu | 2007 |
Intracystic hemorrhage in a mediastinal cystic adenoma causing parathyrotoxic crisis.
Topics: Adenoma; Adult; Bone Density Conservation Agents; Cystadenoma; Diphosphonates; Diuretics; Fluid Ther | 2008 |
Tumor induced hypercalcemia in a patient with mediastinal synovial sarcoma.
Topics: Adolescent; Bone Density Conservation Agents; Diphosphonates; Humans; Hypercalcemia; Male; Mediastin | 2007 |
Pamidronate treatment of hypercalcemia caused by vitamin D toxicity.
Topics: Bone Density Conservation Agents; Calcium; Diphosphonates; Drug Overdose; Humans; Hypercalcemia; Inf | 2007 |
Hypercalcaemia due to malignancy. Role of the kidney and treatment.
Topics: Calcitonin; Calcium; Diphosphonates; Extracellular Space; Fluid Therapy; Glomerular Filtration Rate; | 1982 |
[Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
Topics: Administration, Oral; Adult; Aged; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Female; | 1984 |
[Diphosphonates in the treatment of hypercalcemia].
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Hyperparathyr | 1984 |
[Therapeutic possibilities in paraneoplastic hypercalcemia].
Topics: Adrenal Cortex Hormones; Adult; Aged; Calcitonin; Diphosphonates; Drug Therapy, Combination; Female; | 1981 |
Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
Topics: Adult; Aged; Bone Resorption; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyro | 1982 |
Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Hypercalcemia; Male; Middle Aged; Ne | 1995 |
Intravenous aminohydroxypropylidene bisphosphonate does not modify 99mTc-hydroxymethylene bisphosphonate bone scintigraphy. A prospective study.
Topics: Aged; Bone Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Infusions, Intravenous; Male; M | 1995 |
Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
Topics: Aged; Calcium; Diphosphonates; Female; Homeostasis; Humans; Hypercalcemia; Infusions, Intravenous; K | 1994 |
Paraneoplastic endocrine syndromes.
Topics: Acromegaly; Adrenocorticotropic Hormone; Aminoglutethimide; Bromocriptine; Calcitonin; Cushing Syndr | 1994 |
Intravenous pamidronate sodium therapy in immobilization-related hypercalcemia.
Topics: Acute Kidney Injury; Adult; Diphosphonates; Female; Humans; Hypercalcemia; Immobilization; Injection | 1995 |
Hypercalcaemia in primary oxalosis: role of increased bone resorption and effects of treatment with pamidronate.
Topics: Bone Resorption; Calcium Oxalate; Diphosphonates; Humans; Hypercalcemia; Immunohistochemistry; Kidne | 1995 |
Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Topics: Alendronate; Animals; Autoradiography; Bone and Bones; Bone Resorption; Calcium; Carbon Radioisotope | 1995 |
Effects of the antihypercalcemic drugs gallium nitrate and pamidronate on hormone release of pathologic human parathyroid cells.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Cytoplasm; Diphosphonates; Gallium; Humans; Hypercalcemia; | 1995 |
Pamidronate for cancer-associated hypercalcemia.
Topics: Diphosphonates; Drug Administration Schedule; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1995 |
Increased 1,25-(OH)2D2 concentration in a patient with malignancy-associated hypercalcemia receiving intravenous hyperalimentation inadvertently supplemented with vitamin D2.
Topics: Calcitriol; Contraindications; Diphosphonates; Ergocalciferols; Humans; Hypercalcemia; Male; Middle | 1993 |
Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Topics: Alendronate; Calcitriol; Calcium; Creatinine; Diphosphonates; Female; Humans; Hypercalcemia; Male; N | 1994 |
Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, | 1994 |
[Disodium pamidronate (APD) in therapy of hypercalcemia in primary hyperparathyroidism].
Topics: Aged; Aged, 80 and over; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; | 1994 |
Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
Topics: Bone Neoplasms; Calcium; Cyclic AMP; Diphosphonates; Electrolytes; Humans; Hypercalcemia; Kidney Tub | 1993 |
Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure.
Topics: Calcium Carbonate; Diphosphonates; Female; Humans; Hydroxycholecalciferols; Hypercalcemia; Kidney Fa | 1993 |
Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diphosphonates; Female; Humans; Hypercalcemia | 1994 |
Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate.
Topics: Calcium; Carcinoma; Diphosphonates; Female; Humans; Hypercalcemia; Middle Aged; Pamidronate; Parathy | 1994 |
Evaluation and treatment of hypercalcemia.
Topics: Adenoma; Aged; Bone Neoplasms; Carcinoma, Squamous Cell; Diagnosis, Differential; Diphosphonates; Fe | 1994 |
Effect of aminohydroxypropylidene diphosphonate on the bone metabolism of patients with parathyroid adenoma.
Topics: Adenoma; Adult; Alkaline Phosphatase; Bone and Bones; Calcitriol; Calcium; Creatinine; Diphosphonate | 1993 |
Inhibition of 1,25(OH)2D production by hypercalcemia in osteitis fibrosa cystica: influence on parathyroid hormone secretion and hungry bone disease.
Topics: Adenoma; Alkaline Phosphatase; Bone Resorption; Calcitonin; Calcitriol; Calcium; Calcium Carbonate; | 1993 |
[Results of using Aredia for hypercalcemia in oncology patients].
Topics: Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Drug Evaluation; Female; Humans; Hypercal | 1993 |
Severe immobilization-induced hypercalcemia in a child after liver transplantation successfully treated with pamidronate.
Topics: Alkaline Phosphatase; Calcium; Child; Diphosphonates; Humans; Hypercalcemia; Immobilization; Infusio | 1994 |
Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy.
Topics: Adult; Aged; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Male; Middle Aged; Neoplasms; P | 1993 |
Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphate (APD).
Topics: Adult; Aged; Breast Neoplasms; Calcium; Diphosphonates; Female; Follow-Up Studies; Humans; Hypercalc | 1993 |
Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.
Topics: Adult; Aged; Dihydroxycholecalciferols; Diphosphonates; Female; Humans; Hypercalcemia; Male; Middle | 1993 |
A case of squamous cell lung carcinoma with high concentration of parathyroid hormone-related peptide in serum and pleural effusion presenting hypercalcemia.
Topics: Blotting, Northern; Carcinoma, Squamous Cell; Chromatography, Gel; Diagnosis, Differential; Diphosph | 1993 |
Elevated cytokine levels in a patient with AIDS and hypercalcemia: effects of therapy with pamidronate.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cachexia; Cytokines; Diphosphonates; Humans; Hypercalcemi | 1995 |
Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate.
Topics: Adrenal Cortex Hormones; Adult; Bone Resorption; Calcium; Diphosphonates; Female; Humans; Hydroxycho | 1995 |
Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
Topics: Aged; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyroidism; Infusions, Intrav | 1996 |
Milk-alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism.
Topics: Aged; Anti-Inflammatory Agents; Calcitriol; Calcium Carbonate; Diphosphonates; Emergencies; Female; | 1996 |
An audit of the management of malignant hypercalcaemia.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Clinical Protocols; Diphosphonates; Female; Follow-Up Studi | 1996 |
Safety of pamidronate in patients with renal failure and hypercalcemia.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Creatinine; Diphosphonates; Female; Follow-Up Studies; Huma | 1996 |
Iritis following intravenous pamidronate.
Topics: Aged; Diphosphonates; Female; Humans; Hypercalcemia; Iritis; Male; Middle Aged; Osteitis Deformans; | 1996 |
Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D | 1995 |
Symptomatic hypocalcemia after intravenous pamidronate.
Topics: Aged; Alberta; Carcinoma, Transitional Cell; Diphosphonates; Female; Humans; Hypercalcemia; Hypocalc | 1996 |
Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate.
Topics: Adult; Breast Neoplasms; Diphosphonates; Fatal Outcome; Female; Humans; Hypercalcemia; Infant, Newbo | 1996 |
Effects of bisphosphonate (pamidronate) on bone resorption resulting from metastasis of a squamous cell carcinoma: report of an autopsy case and evaluation of bone resorbing activity in an experimental animal model.
Topics: Acid Phosphatase; Aged; Animals; Bone Neoplasms; Bone Resorption; Carcinoma, Squamous Cell; Diphosph | 1996 |
[Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma].
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Hypercalcemia; | 1996 |
Pamidronate (Aredia) and zoledronate: update on clinical results. Introduction.
Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Organophosphorus Compounds; Osteo | 1996 |
Pamidronate (Aredia).
Topics: Bone Resorption; Diphosphonates; Humans; Hypercalcemia; Osteoclasts; Pamidronate | 1996 |
Pamidronate in the treatment of bone metastases--the European experience.
Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Europe; Humans; Hypercalc | 1996 |
Zoledronate: the preclinical pharmacology.
Topics: Animals; Bone Resorption; Cholecalciferol; Depression, Chemical; Diphosphonates; Disease Models, Ani | 1996 |
Hypercalcaemia in osteogenesis imperfecta treated with pamidronate.
Topics: Adolescent; Diphosphonates; Fractures, Spontaneous; Humans; Hypercalcemia; Male; Osteogenesis Imperf | 1997 |
Acute pseudogout as a complication of pamidronate.
Topics: Aged; Chondrocalcinosis; Diphosphonates; Female; Humans; Hypercalcemia; Pamidronate | 1997 |
Treatment of immobilisation hypercalcaemia in acute intermittent porphyria: experience from three cases.
Topics: Acute Disease; Adolescent; Adult; Diphosphonates; Female; Humans; Hypercalcemia; Pamidronate; Porphy | 1997 |
Long-term management of hypercalcaemia in chronically active sarcoidosis.
Topics: Adult; Chronic Disease; Diphosphonates; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Hy | 1997 |
Childhood cancer and hypercalcemia: report of a case treated with pamidronate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcitonin; Child, Preschool; Diphosphonates; Glucoc | 1997 |
Hypercalcemia in an AIDS patient treated with growth hormone.
Topics: Acquired Immunodeficiency Syndrome; Adult; Calcium; Diphosphonates; Growth Hormone; HIV Wasting Synd | 1997 |
Use of pamidronate in the management of acute cancer-related hypercalcemia in children.
Topics: Acute Disease; Adolescent; Calcium; Child; Child, Preschool; Diphosphonates; Female; Humans; Hyperca | 1998 |
Immobilization hypercalcemia in incomplete paraplegia: successful treatment with pamidronate.
Topics: Adolescent; Adult; Diphosphonates; Humans; Hypercalcemia; Male; Pamidronate; Paraplegia | 1998 |
[Bone metastases: pathogenesis and treatment with diphosphonates].
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Neoplasm Proteins; Ost | 1997 |
Rapid skeletal turnover and hypercalcemia associated with markedly elevated interleukin-6 levels in a young black man.
Topics: Adult; Alendronate; Alkaline Phosphatase; Black People; Bone and Bones; Bone Remodeling; Collagen; C | 1998 |
Use of pamidronate in the management of acute cancer-related hypercalcemia in children.
Topics: Antineoplastic Agents; Child; Diphosphonates; Humans; Hypercalcemia; Hypocalcemia; Hypophosphatemia; | 1998 |
Disseminated coccidioidomycosis associated with hypercalcemia.
Topics: Adult; Antifungal Agents; Bone and Bones; Coccidioidomycosis; Diphosphonates; Humans; Hypercalcemia; | 1998 |
Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Calcitriol | 1998 |
Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro.
Topics: Animals; Arteries; Calcium Channel Blockers; Clodronic Acid; Diphosphonates; Drug Synergism; Etidron | 1998 |
Hypercalcemia in malignant paraganglioma due to parathyroid hormone-related protein.
Topics: Adolescent; Diphosphonates; Humans; Hypercalcemia; Male; Pamidronate; Paraganglioma; Parathyroid Hor | 1998 |
The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.
Topics: Aged; Diphosphonates; Drug Overdose; Female; Humans; Hypercalcemia; Iatrogenic Disease; Pamidronate; | 1998 |
The use of pamidronate in three children with renal disease.
Topics: Adolescent; Anti-Inflammatory Agents; Bone Density; Bone Diseases, Metabolic; Child; Diphosphonates; | 1998 |
Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.
Topics: Adenocarcinoma; Adenoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 1998 |
Bisphosphonates for metastatic bone pain.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; | 1999 |
Use of disodium pamidronate in children with hypercalcemia awaiting liver transplantation.
Topics: Child; Child, Preschool; Diphosphonates; Drug Administration Schedule; Female; Humans; Hypercalcemia | 1998 |
Hypercalcemia in an euthyroid patient with secondary hypoadrenalism and diabetes insipidus due to hypothalamic tumor.
Topics: Acute Kidney Injury; Adrenal Insufficiency; Adult; Antineoplastic Agents; Diabetes Insipidus; Diphos | 1998 |
Brief report: Medulloblastoma with widespread skeletal metastases presenting with hypercalcemia.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Cerebellar Neoplasms; Diphosphonates; Female; Hum | 1999 |
[A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Di | 1999 |
Metabolic disturbances after a single dose of 30 mg pamidronate for leukaemia-associated hypercalcaemia in a 11-year-old boy.
Topics: Antineoplastic Agents; Calcium; Child; Diphosphonates; Humans; Hypercalcemia; Hypocalcemia; Leukemia | 1999 |
Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury.
Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents; Calcium; Diphosphonates; Dose-Response R | 1999 |
Use of pamidronate to reverse vitamin D3-induced toxicosis in dogs.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Blood Chemical Analysis; Calcitonin; Cholecalciferol; | 1999 |
Use of bisphosphonates in hypercalcemia associated with childhood cancer.
Topics: Antineoplastic Agents; Child; Diphosphonates; Dose-Response Relationship, Drug; Humans; Hypercalcemi | 1999 |
[Two cases of malignancy-associated hypercalcemia from bone metastases of breast cancer successfully treated with combination therapy using pamidronate and calcitonin].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcitonin; Consciousness Disorders; Diphos | 2000 |
Effects of fasting, feeding, and bisphosphonate administration on serum calcitriol levels in phosphate-deprived rats.
Topics: Animals; Antineoplastic Agents; Calcitriol; Calcium; Diphosphonates; Eating; Fasting; Hypercalcemia; | 2000 |
[Immobilization hypercalcemia as a complication of polyneuropathy].
Topics: Anti-Inflammatory Agents; Calcium; Diphosphonates; Humans; Hypercalcemia; Immobilization; Male; Midd | 2000 |
Overdosage of pamidronate in a patient with renal cell carcinoma.
Topics: Aged; Anti-Inflammatory Agents; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Hypercalcemia | 2000 |
Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcem | 2000 |
Positive effect of radiotherapy and surgery on hormonally active pulmonary metastases of primary parathyroid carcinoma.
Topics: Antineoplastic Agents; Calcium; Combined Modality Therapy; Diphosphonates; Female; Follow-Up Studies | 2000 |
Tumor 'flare' hypercalcemia--an additional indication for bisphosphonates?
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasm | 2001 |
Intravenous bisphosphonate for hypercalcemia accompanying subcutaneous fat necrosis: a novel treatment approach.
Topics: Diphosphonates; Fat Necrosis; Humans; Hypercalcemia; Infant; Infusions, Intravenous; Male; Pamidrona | 2001 |
Hypercalcemia in patients with oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Calcitonin; Carcinoma, Squamous Cell; Diphosphona | 2001 |
Bones, groans and blasts.
Topics: Adolescent; Antineoplastic Agents; Diagnosis, Differential; Diphosphonates; Female; Humans; Hypercal | 2001 |
Effect of pamidronate in a rat hypercalcemia model induced by cholecalciferol.
Topics: Animals; Body Weight; Calcitonin; Calcium; Cholecalciferol; Diphosphonates; Female; Hypercalcemia; P | 1992 |
Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.
Topics: Absorption; Calcium; Cyclic AMP; Diphosphonates; Humans; Hypercalcemia; Infusions, Intravenous; Kidn | 1992 |
Pamidronate use in two cases of hypercalcaemia secondary to hyperparathyroidism.
Topics: Aged; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyroidism; Pamidronate | 1992 |
Treatment of resistant tumor-induced hypercalcemia with escalating doses of pamidronate (APD).
Topics: Bone Resorption; Diphosphonates; Drug Resistance; Female; Humans; Hypercalcemia; Middle Aged; Neopla | 1992 |
[Combination therapy with pamidronate and calcitonin in hypercalcemic crisis caused by primary hyperparathyroidism].
Topics: Aged; Calcitonin; Diphosphonates; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Hyperpar | 1992 |
Recovery of parathyroid hormone secretion during correction of tumor-associated hypercalcemia.
Topics: Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Male; Middle Aged; Neoplasms; Pamidronate; P | 1992 |
Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD).
Topics: Calcium; Diphosphonates; Humans; Hypercalcemia; Neoplasm Proteins; Neoplasms; Pamidronate; Parathyro | 1992 |
Pamidronate.
Topics: Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Hyperparathyroidism; Neoplasms; Ost | 1992 |
A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia.
Topics: Calcium; Creatinine; Diphosphonates; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1991 |
Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hy | 1991 |
Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient.
Topics: Adolescent; Biopsy; Calcium; Diphosphonates; Humans; Hypercalcemia; Ilium; Immobilization; Male; Ost | 1991 |
Intravenous pamidronic acid in hypercalcemia due to parathyroid carcinoma.
Topics: Adult; Diphosphonates; Female; Humans; Hypercalcemia; Infusions, Intravenous; Male; Middle Aged; Pam | 1991 |
Symptomatic hypercalcaemia in lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Calcitonin; Diphosphonates; Drug Therapy, Combination; Female; Human | 1991 |
Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
Topics: Animals; Bone and Bones; Bone Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hyp | 1991 |
Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
Topics: Adolescent; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyroid | 1991 |
Relative role of bone and kidney in the hypercalcaemia associated with the rat Walker carcinosarcoma 256.
Topics: Amifostine; Animals; Bone and Bones; Calcium; Carcinoma 256, Walker; Diphosphonates; Female; Hyperca | 1991 |
Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
Topics: Aged; Calcium; Cyclic AMP; Diphosphonates; Female; Glomerular Filtration Rate; Humans; Hypercalcemia | 1991 |
Comment on "Use of aminohydroxypropylidene bisphosphonate (AHPrBP, "APD") for the treatment of hypercalcemia in patients with renal impairment" by Yap et al.
Topics: Diphosphonates; Humans; Hypercalcemia; Pamidronate; Renal Dialysis | 1991 |
Use of bisphosphonates in hypercalcaemia due to malignancy.
Topics: Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1990 |
Chronic high-dose pamidronate in refractory malignant hypercalcaemia.
Topics: Diphosphonates; Drug Tolerance; Humans; Hypercalcemia; Male; Middle Aged; Multiple Myeloma; Pamidron | 1990 |
Dose of bisphosphonate for hypercalcaemia of malignancy.
Topics: Aged; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Hypercalcemia; Infusions, Intravenous; | 1990 |
Malignant osteopetrosis: hypercalcaemia after bone marrow transplantation.
Topics: Bone Marrow Transplantation; Calcitonin; Child, Preschool; Diphosphonates; Female; Humans; Hypercalc | 1991 |
The role of 1,25-dihydroxyvitamin D in the maintenance of hypercalcemia in a patient with an ovarian carcinoma producing parathyroid hormone-related protein.
Topics: Aged; Bone Resorption; Calcitriol; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Ovarian N | 1991 |
Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Calcitonin; Diphosphonates; Dru | 1990 |
Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
Topics: Aged; Calcitonin; Diphosphonates; Drug Therapy, Combination; Female; Fluid Therapy; Humans; Hypercal | 1990 |
Leukaemia-associated hypercalcaemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate.
Topics: Calcium; Child; Diphosphonates; Humans; Hypercalcemia; Leukemia; Male; Pamidronate | 1990 |
Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.
Topics: Adult; Calcium; Creatinine; Diphosphonates; Female; Humans; Hypercalcemia; Immobilization; Male; Mid | 1990 |
Use of aminohydroxypropylidene bisphosphonate (AHPrBP, "APD") for the treatment of hypercalcemia in patients with renal impairment.
Topics: Acute Kidney Injury; Adult; Diphosphonates; Female; Humans; Hypercalcemia; Kidney Failure, Chronic; | 1990 |
No effect of APD (amino hydroxypropylidene bisphosphonate) on hypercalcemia in patients with renal osteodystrophy.
Topics: Adult; Chronic Kidney Disease-Mineral and Bone Disorder; Diphosphonates; Female; Humans; Hypercalcem | 1990 |
Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone.
Topics: Bone and Bones; Breast Neoplasms; Calcium; Carcinoma, Squamous Cell; Diphosphonates; Female; Humans; | 1990 |
Posttraumatic parathyroid crisis and severe hypercalcemia treated with intravenous bisphosphonate (APD). Case report.
Topics: Abdominal Injuries; Acute Disease; Brain Concussion; Diphosphonates; Female; Humans; Hypercalcemia; | 1990 |
Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.
Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Infusions, Intravenous; Kidney; Neoplasms; Pa | 1989 |
Pamidronate and hypercalcaemia of malignancy.
Topics: Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Drug Evaluation; Female; Humans; Hyperc | 1989 |
One-shot high-dose pamidronate disodium (APD): effective, simple treatment for hypercalcaemia in haematological malignancy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Diphosphonates; Drug Administration Schedule; | 1989 |
Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy.
Topics: Adolescent; Diphosphonates; Humans; Hypercalcemia; Immobilization; Infusions, Intravenous; Male; Pam | 1989 |
Treatment of tumor-induced osteolysis by APD.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Rela | 1989 |
Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
Topics: Adult; Aged; Diphosphonates; Female; Follow-Up Studies; Humans; Hypercalcemia; Hypocalcemia; Infusio | 1989 |
Single high dose aminohydroxypropylidene diphosphonate infusions to treat cancer-associated hypercalcaemia.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Hypercalcemi | 1986 |
Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate.
Topics: Diphosphonates; Female; Humans; Hypercalcemia; Hypocalcemia; Middle Aged; Pamidronate | 1987 |
Treatment of severe hypercalcaemia with mithramycin and aminohydroxypropylidene bisphosphonate.
Topics: Diphosphonates; Drug Therapy, Combination; Humans; Hypercalcemia; Pamidronate; Plicamycin | 1988 |
Malignancy-associated hypercalcaemia: relationship between mechanisms of hypercalcaemia and response to antihypercalcaemic therapy.
Topics: Calcitonin; Diphosphonates; Humans; Hypercalcemia; Neoplasms; Pamidronate; Plicamycin | 1987 |
New inhibitors of osteolysis: implications for hypercalcemia and bone metastases.
Topics: Amifostine; Bone Neoplasms; Bone Resorption; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; | 1986 |
Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Cyclic AMP; Diphosphonates; Female; Head and | 1986 |
Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
Topics: Bone Resorption; Calcitonin; Calcium; Creatinine; Diphosphonates; Drug Therapy, Combination; Humans; | 1986 |
Dose-dependent effect of AHPrBP in malignant hypercalcemia: wishful thinking and facts.
Topics: Diphosphonates; Dose-Response Relationship, Drug; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1988 |
Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate.
Topics: Adult; Diphosphonates; Female; Humans; Hypercalcemia; Infusions, Intravenous; Male; Pamidronate; Thy | 1988 |
Treatment of refractory cancer-associated hypercalcemia with aminohydroxypropylidene diphosphonate.
Topics: Adenocarcinoma; Antineoplastic Agents; Diphosphonates; Female; Humans; Hypercalcemia; Lung Neoplasms | 1988 |
Treatment of hypercalcemia of malignancy with intermittent single infusions of 3-amino-1-hydroxypropylidene-1, 1-biphosphonate (APD)
Topics: Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Hypercalcemia; Middl | 1988 |
Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia.
Topics: Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hype | 1988 |
Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Creatinine; Diphosphonates; Dose-Response Relationship, Dru | 1988 |
[Bone metastases and hypercalcemia in cancer].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcem | 1988 |
A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.
Topics: Bone Neoplasms; Calcium; Diphosphonates; Drug Administration Schedule; Female; Humans; Hypercalcemia | 1987 |
Aminohydroxypropylidene diphosphonate treatment of hypercalcemic crisis due to primary hyperparathyroidism.
Topics: Adult; Diphosphonates; Humans; Hypercalcemia; Hyperparathyroidism; Male; Pamidronate | 1987 |
A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Infusions, I | 1986 |
Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD.
Topics: Calcium; Diphosphonates; Humans; Hypercalcemia; Osteitis Deformans; Pamidronate; Parathyroid Hormone | 1986 |
Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
Topics: Adult; Aged; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Hypercalcemia; Male; | 1987 |
3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Calcium; Diphosphonates; Female; Fluid Therapy; Humans; Hydroxyprolin | 1987 |
Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy.
Topics: Administration, Oral; Aged; Diphosphonates; Female; Humans; Hypercalcemia; Infusions, Parenteral; Ma | 1986 |
Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment.
Topics: Calcium; Diphosphonates; Humans; Hypercalcemia; Male; Middle Aged; Pamidronate; Retrospective Studie | 1986 |
[Treatment of hypercalcemia].
Topics: Diphosphonates; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1986 |